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ABSTRACT	  
Background:	   Irritable	   bowel	   syndrome	   (IBS)	   is	   a	   disorder	   characterized	   by	  abdominal	   pain	   or	   discomfort	   combined	   with	   altered	   bowel	   habits	   and	   is	  associated	   with	   impaired	   quality	   of	   life.	   The	   prevalence	   of	   IBS	   in	   the	   general	  adult	   population	   is	   approximately	   10%.	   Psychological	   factors	   have	   been	  implicated	   in	   IBS	   because	   of	   high	   rates	   of	   comorbidity	   with	   psychiatric	  diagnoses	  and	  the	  fact	  that	  stress	  can	  cause	  IBS	  symptoms.	  Several	  studies	  have	  been	  conducted	  on	  psychological	  treatment	  for	  IBS.	  Most	  of	  these	  have	  studied	  cognitive	   behavior	   therapy	   (CBT)	   but	   show	   inconsistent	   results.	   Although	  symptom-­‐related	   fear	   and	   avoidance	   behaviors	   have	   been	   found	   to	   play	   an	  important	   role	   in	   IBS,	   no	   psychological	   treatment	   has	   targeted	   these	   factors	  primarily.	   The	   “third	   wave”	   of	   cognitive	   behavioral	   therapies	   promotes	  acceptance	   and	   behavioral	   flexibility	   in	   the	   presence	   of	   aversive	   experiences,	  such	  as	  IBS	  symptoms.	  Exposure	  treatment	  is	  a	  behavioral	  intervention	  aimed	  at	  decreasing	   fear	   of	   arbitrary	   stimuli.	   Given	   the	   high	   prevalence	   of	   IBS,	   there	   is	  need	  for	  delivery	  formats	  that	  allow	  more	  patients	  to	  gain	  access	  to	  treatment.	  Internet-­‐delivered	  cognitive	  behavior	  therapy	  with	  online	  therapist	  support	  has	  shown	  effectiveness	  in	  treating	  both	  psychiatric	  disorders	  and	  disorders	  within	  the	  behavioral	  medicine	  field.	  
Aims:	   The	   general	   aim	   of	   the	   present	   thesis	   was	   to	   develop	   and	   evaluate	   an	  effective	  psychological	  treatment	  for	  IBS	  that	  can	  be	  made	  accessible	  to	  a	  large	  number	   of	   IBS	   patients.	  We	   developed	   an	   exposure-­‐based	   CBT	   treatment	   that	  emphasized	   acceptance	   and	   behavioral	   flexibility	   in	   response	   to	   IBS-­‐related	  experiences.	  Specific	  aims	  of	  this	  thesis	  were	  to:	  a)	  evaluate	  exposure-­‐based	  CBT	  as	  a	  group	  treatment	  for	  IBS	  (study	  I),	  b)	  evaluate	  exposure-­‐based	  CBT	  delivered	  via	  the	  internet	  (ICBT)	  for	  IBS	  (study	  II),	  c)	  evaluate	  the	  long-­‐term	  effectiveness	  of	   ICBT	   for	   IBS	   (study	   III),	   d)	   evaluate	   the	   effectiveness	   and	   clinical	   utility	   of	  ICBT	  for	  IBS	  (study	  IV),	  and	  e)	  evaluate	  the	  specificity	  of	  ICBT	  for	  IBS	  (study	  V).	  
Methods:	   Study	   I	   included	   34	   referred	   female	   IBS	   patients	   who	   underwent	  exposure-­‐based	  CBT	   in	  group	   format.	  Study	   II	   randomized	  85	  self-­‐referred	   IBS	  patients	  to	  ICBT	  or	  waiting	  list.	  Study	  III	  was	  a	  long-­‐term	  follow-­‐up	  of	  study	  II,	  75	   of	   the	   original	   study’s	   85	  participants	   (88%)	  participated	   in	   the	  15-­‐	   to	   18-­‐month	  follow-­‐up.	  Study	  IV	  randomized	  62	  consecutively	  recruited	  patients	  at	  a	  gastroenterological	  clinic	   to	   ICBT	  or	  waiting	   list.	  Study	  V	  randomized	  195	  self-­‐referred	   IBS	   patients	   to	   ICBT	   or	   internet-­‐delivered	   stress	   management.	   The	  stress-­‐management	   condition	  was	   designed	   to	   control	   for	   effects	   of	   treatment	  credibility,	   expectancy	   of	   improvement,	   and	   attention	   from	   a	   caregiver.	   The	  treatment	  conditions	  in	  all	  studies	  lasted	  for	  10	  weeks.	  
Results:	   In	  all	   studies	  exposure-­‐based	  CBT	  was	  associated	  with	   improvements	  in	   IBS	  symptoms,	   IBS-­‐related	  fear,	  and	  quality	  of	   life.	   In	  studies	   II	  and	  IV,	   ICBT	  was	  more	  effective	   than	  a	  waiting	   list	  and	   in	  study	  V,	   ICBT	  was	  more	  effective	  
	  vi	  
than	  internet-­‐delivered	  stress	  management.	  Study	  I	  also	  showed	  that	  exposure-­‐based	  CBT	  leads	  to	  improvement	  in	  mental	  health.	  
Conclusions:	   Exposure-­‐based	  CBT	   is	   effective	  both	   in	   group	   format	   and	  when	  delivered	   via	   internet.	   Both	   self-­‐referred	   and	   clinical	   samples	   of	   IBS	   patients	  improve	   from	   the	   treatment.	   The	   effects	   of	   exposure-­‐based	   CBT	   cannot	   be	  explained	   by	   non-­‐specific	   factors	   such	   as	   treatment	   credibility,	   expectancy	   of	  improvement,	   and	   attention	   from	   a	   caregiver.	   ICBT	   is	   a	   promising	   new	  treatment	   modality	   that	   can	   be	   made	   accessible	   to	   a	   large	   number	   of	   IBS	  patients.	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1. INTRODUCTION	  Irritable	  bowel	  syndrome	  (IBS)	  is	  a	  highly	  prevalent	  disorder	  that	  is	  associated	  with	  individual	  suffering	  and	  societal	  costs.	  Many	  psychological	  treatments	  have	  been	  developed	  for	  IBS	  and	  show	  mixed	  results.	  Despite	  a	  clear	  role	  of	  symptom-­‐related	   stress	   in	   symptom	   exacerbation	   and	   presence	   of	   excessive	   symptom	  controlling	   and	   avoidance	   behaviors	   in	   IBS,	  most	   psychological	   treatments	   do	  not	   primarily	   target	   these	   factors.	   There	   is	   also	   a	   lack	   of	   availability	   of	   these	  treatments,	  meaning	   that	  most	   IBS	   patients	   cannot	   gain	   access	   to	   an	   effective	  treatment.	  I	  began	  my	  work	  on	  this	  thesis	  in	  the	  summer	  of	  2005.	  My	  aim	  was	  to	  participate	  in	  the	  development	  and	  evaluation	  of	  a	  new	  psychological	  treatment	  for	  IBS	  that	  could	  be	  made	  available	  for	  a	  large	  number	  of	  IBS	  patients.	  I	  had	  just	  finished	  my	  studies	   at	   the	   psychology	   program	   and	   my	   training	   in	   cognitive	   behavior	  therapy	  (CBT)	  had	  been	  influenced	  by	  acceptance	  and	  commitment	  therapy.	  The	  emphasis	  of	  my	  clinical	  training	  had	  been	  on	  helping	  clients	  to	  remain	  in	  contact	  with	  negative	  experiences	  while	  engaging	  in	  behaviors	  that	  purposefully	  moved	  them	  in	  their	  valued	  life	  direction.	  When	  meeting	  patients	  with	  IBS,	   I	  observed	  that	  most	   of	   them	  did	  not	  want	   to	   experience	   IBS	   symptoms	  and	   the	  negative	  emotions	  that	  were	  associated	  with	  these	  symptoms.	  They	  therefore	  engaged	  in	  behaviors	   that	   served	   to	   avoid	   symptoms	   and	   symptom-­‐related	   experiences.	  This	  behavioral	  pattern	  did	  certainly	  not	  help	  them	  to	  live	  a	  rich	  and	  full	  life.	  I	  wanted	  see	  if	  a	  treatment	  based	  on	  accepting	  IBS	  symptoms	  and	  the	  emotions	  and	  thoughts	  that	  were	  associated	  with	  IBS	  could	  help	  these	  patients.	  I	  also	  saw	  a	   clear	   need	   for	   these	   patients	   to	   willingly	   expose	   themselves	   to	   these	  symptoms,	  emotions,	  and	  thoughts	  to	  relieve	  the	  fear	  and	  anxiety	  they	  had	  come	  to	  associate	  with	  them.	  This	  constituted	  the	  foundation	  for	  exposure-­‐based	  CBT	  with	  emphasis	  on	  acceptance	  of	  IBS	  symptoms	  and	  related	  experiences.	  My	   supervisors	   and	   our	   research	   group	  were	   then,	   and	   still	   are,	   involved	   the	  development	   of	   the	   “Swedish	   model”	   of	   internet-­‐delivered	   cognitive	   behavior	  therapy	   (ICBT).	   I	   had	   also	   written	  my	  master’s	   thesis	   about	   ICBT	   for	   bulimia	  nervosa	   and	  binge	   eating	  disorder.	  Delivering	   the	   exposure-­‐based	  CBT	   for	   IBS	  over	  the	  internet	  would	  mean	  that	  a	  lot	  more	  patients	  could	  be	  treated.	  For	  this	  purpose,	  I	  programmed	  a	  web	  platform	  that	  could	  be	  used	  to	  deliver	  ICBT.	  That	  platform	  has	  since	  then	  been	  used	  in	  numerous	  studies	  and	  in	  the	  world’s	  first	  psychiatric	  ICBT	  clinic.	  	  This	   thesis	  describes	  my,	  my	  colleagues’,	  and	  my	  supervisors’	  work	   to	  develop	  and	  evaluate	  a	  new	  treatment	  protocol	  and	  new	  treatment	  format	  for	  IBS.	  
	  
Stockholm,	  Linköping,	  Spannarboda,	  January-­‐April	  2011.	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BACKGROUND	  
1.1 EPIDEMIOLOGY	  OF	  IBS	  
1.1.1 DIAGNOSIS	  Irritable	   bowel	   syndrome	   is	   the	   presence	   of	   recurring	   symptoms	   in	   the	   lower	  gastrointestinal	  (GI)	  tract,	  primarily	  abdominal	  pain	  or	  discomfort,	  constipation,	  and/or	   diarrhea,	   which	   cannot	   be	   explained	   by	   any	   structural	   lesions	   (1,	   2).	  There	  are	  potential	  serious	  illnesses	  that	  can	  present	  with	  these	  symptoms,	  most	  commonly	   inflammatory	  bowel	  disease	   (Crohn’s	  disease	  and	  ulcerative	   colitis)	  and	  colorectal	  cancer	  (2).	  Based	  on	  this	  definition,	   it	  could	  be	  said	  that	  IBS	  is	  a	  diagnosis	   of	   exclusion,	   i.e.	   it	   can	   only	   be	   made	   if	   other	   explanations	   for	   the	  symptoms	  have	  been	  ruled	  out.	  However,	  using	  absence	  of	  organic	  illnesses	  as	  a	  primary	   diagnostic	   criterion	   has	   proven	   to	   lead	   to	   extensive	   medical	  examinations	  and	  tests	  in	  order	  to	  rule	  them	  out	  as	  causes	  of	  the	  symptoms	  (1,	  3).	   Most	   often	   the	   findings	   are	   negative	   and	   the	   patient	   ends	   up	   with	   an	   IBS	  diagnosis	   (4,	   5).	   Therefore,	   several	   efforts	   have	  been	  made	   to	   develop	   criteria	  that	  can	  be	  used	  to	  establish	  a	  positive	  diagnosis	  of	  IBS	  and	  avoid	  unnecessary	  testing	  and	  examinations.	  In	   1978,	  Manning	   et	   al.	   published	   the	   first	   set	   of	   diagnostic	   criteria	   that	  were	  based	  on	   their	   ability	   to	  distinguish	   IBS	   from	   inflammatory	  bowel	  disease	   (1).	  The	   Manning	   criteria	   included	   abdominal	   pain	   relieved	   by	   defecation,	   looser	  and/or	  more	  frequent	  stools	  with	  onset	  of	  pain,	  abdominal	  distension,	  passage	  of	   mucus	   in	   stools,	   and	   sense	   of	   incomplete	   evacuation.	   In	   1984,	   Kruis	   et	   al.	  created	  a	   set	  of	   criteria	   that	  also	   included	   “alarm	  symptoms”,	   such	  as	  blood	   in	  stool	   and	  weight	   loss,	   that	   could	   be	   indicative	   of	   organic	   illness	   (6).	  However,	  because	  of	  a	  complicated	  scoring	  system	  these	  criteria	  were	  never	  widely	  used	  (7).	  Besides	  being	  an	  aid	  in	  excluding	  organic	  illness,	  objective	  diagnostic	  criteria	  are	  also	  important	  within	  clinical	  research.	  In	  a	  review	  of	  treatment	  trials	  of	  IBS	  in	  1988,	  Klein	  noted	  that	  “not	  a	  single	   IBS	  treatment	   trial	  reported	  to	  date	  has	  used	  an	  adequate	  operational	  definition	  of	  IBS”	  (8	  p.	  233).	  To	  meet	  the	  need	  for	  reliable	   diagnostic	   criteria	   that	   could	   also	   be	   used	   in	   research,	   the	   Rome	  committee	  was	  established	  in	  the	  late	  1980s	  (9).	  In	  the	  following	  years	  several	  renditions	  of	  diagnostic	  criteria	  for	  IBS	  were	  published:	  the	  Rome	  I	  (1992;	  10),	  Rome	   II	   (1999;	   11),	   and	  Rome	   III	   (2006;	   12).	   The	   latest	   version,	   the	  Rome	   III	  criteria,	  are	  shown	  in	  Box	  1.	  The	  Rome	  criteria	  introduced	  pain	  or	  discomfort	  as	  mandatory	   symptoms	   in	   IBS	   together	   with	   symptom	   chronicity	   and	   minimal	  thresholds	   for	   symptom	   frequency.	   Common	   symptoms	   such	   as	   bloating	   and	  feeling	   of	   incomplete	   evacuation	   support	   the	  diagnosis	   but	   are	  not	   part	   of	   the	  Rome	   III	   criteria.	   There	   are	   also	   Rome	   criteria	   for	   classifying	   IBS	   subgroups	  according	   to	   symptom	   predominance,	   namely	   IBS	   with	   constipation,	   IBS	   with	  diarrhea,	  mixed	  IBS,	  and	  unsubtyped	  IBS	  (12).	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Box	  1.	  Rome	  III	  diagnostic	  criteria	  for	  IBS.	  
Recurrent	  abdominal	  pain	  or	  discomfort*	  at	  least	  3	  days	  per	  month	  in	  the	  last	  3	  months	  associated	  
with	  2	  or	  more	  of	  the	  following:	  
	  
1. Improvement	  with	  defecation	  	  
2. Onset	  associated	  with	  a	  change	  in	  frequency	  of	  stool	  
3. Onset	  associated	  with	  a	  change	  in	  form	  (appearance)	  of	  stool	  
	  
Criteria	  fulfilled	  for	  the	  last	  3	  months	  with	  symptom	  onset	  at	  least	  6	  months	  prior	  to	  diagnosis.	  
	  
*Discomfort	  means	  an	  uncomfortable	  sensation	  not	  described	  as	  pain.	  
	  
Supportive	  symptoms	  that	  are	  not	  part	  of	  the	  diagnostic	  criteria	  include:	  
• Abnormal	  stool	   frequency:	  ≤	  3	  bowel	  movements	  per	  week	  or	  >	  3	  bowel	  movements	  per	  
day)	  	  
• Abnormal	  stool	  form:	  lumpy/hard	  stool	  or	  loose/watery	  stool	  
• Defecation	  straining	  
• Urgency	  
• Feeling	  of	  incomplete	  bowel	  movement	  
• Passing	  of	  mucus	  
• Bloating	  
	  	  
1.1.2 PREVALENCE	  The	   prevalence	   estimates	   of	   IBS	   vary	   considerably	   between	   epidemiological	  studies.	   Using	   Rome	   I	   and	   II	   criteria,	   Bommelaer	   et	   al.	   (13)	   estimated	   the	  prevalence	  of	  IBS	  to	  be	  1-­‐2%	  while	  Ólafsdóttir	  et	  al.	  (14)	  estimated	  a	  prevalence	  of	  32%	  using	  Manning	  criteria.	  This	  variation	  is	  judged	  to	  be	  a	  reflection	  of	  the	  different	   definitions	   of	   IBS,	   where	   Manning	   criteria	   are	   more	   inclusive	   than	  Rome	  I-­‐III	  criteria	  (15).	  In	  the	  Ólafsdóttir	  study,	  using	  Rome	  II	  and	  III	  criteria	  on	  the	   same	   population	   of	   799	   adult	   Icelanders,	   gave	   estimates	   of	   5%	   and	   13%,	  respectively	  (14).	  Hahn	  et	  al.	  published	  data	  from	  a	  large	  US	  health	  survey	  with	  42,392	   respondents,	   which	   showed	   that	   about	   3.5%	   of	   the	   respondents	  identified	  themselves	  as	  having	  IBS.	  Of	  these,	  about	  50%	  fulfilled	  neither	  Rome	  I	  nor	  Manning	  criteria	   (16).	  The	  “true”	  prevalence	  of	   IBS	   is	   therefore	  difficult	   to	  determine,	   but	   comprehensive	   reviews	   have	   concluded	   that	   IBS	   affects	   about	  10%	   of	   the	   adult	   population	   (15,	   17).	   The	   prevalence	   of	   IBS	   among	   females	  compared	  to	  males	  has	  been	  found	  to	  be	  about	  twice	  as	  large	  (18)	  and	  IBS	  seems	  to	  be	  most	  common	  in	  the	  ages	  between	  20	  and	  40	  (19).	  
1.1.3 NATURAL	  COURSE	  AND	  QUALITY	  OF	  LIFE	  IBS	   is	  considered	   to	  be	  a	  chronic	  disorder	   (17).	   In	   two	  population	  studies	   that	  investigated	  the	  10-­‐year	  natural	  history	  of	  IBS,	  67%	  (20)	  and	  43%-­‐61%	  (14)	  of	  patients	   who	   had	   been	   diagnosed	   with	   IBS	   retained	   their	   diagnosis	   after	   10	  years.	   In	   a	   Swedish	   population	   study,	   55%	   of	   IBS	   patients	   retained	   their	  diagnosis	   after	   7	   years,	   but	   notably	   only	   13%	  were	   symptom-­‐free	  while	   21%	  reported	   minor	   GI	   symptoms	   and	   11%	   were	   diagnosed	   with	   functional	  dyspepsia	   or	   reflux	   disease	   (21).	   In	   a	   12-­‐year	   follow-­‐up	   study,	   30%	   of	   IBS	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patients	   were	   symptom-­‐free	   at	   follow-­‐up	   while	   25%	   were	   diagnosed	   with	  another	   functional	   GI	   disorder	   (22).	   Although	   IBS	   is	   chronic	   for	   a	  majority	   of	  patients	   it	   has	   not	   been	   associated	   with	   long-­‐term	   (over	   20	   years)	   increased	  mortality	  (23)	  or	  susceptibility	  to	  organic	  illness	  (24).	  Much	  research	  has	   investigated	  the	   impact	  of	   IBS	  on	  quality	  of	   life.	  Within	  this	  context,	   the	   specific	   term	   is	   health-­‐related	   quality	   of	   life,	   which	   covers	   the	  physical,	   psychological,	   and	   social	   domains	   of	   health	   (25).	   In	   a	   review	   it	   was	  concluded	   that	   IBS	   patients	   have	   impaired	   health-­‐related	   quality	   of	   life	   in	   all	  three	   domains	   compared	   to	   normal	   controls	   and	   that	   symptom	   severity	   is	  negatively	  correlated	  with	  health-­‐related	  quality	  of	  life	  (26).	  
1.1.4 SOCIETAL	  COSTS	  IBS	   is	   also	   associated	   with	   productivity	   loss	   and	   health	   care	   expenditure.	  Compared	  with	  normal	  controls,	  IBS	  patients	  have	  nearly	  tripled	  work	  or	  school	  absenteeism	  (18).	   IBS	  patients	  also	  report	   that	  20%	  of	   their	  work	  time	   is	  non-­‐productive	  while	  their	  colleagues	  without	  IBS	  report	  that	  6%	  of	  their	  work	  time	  is	   non-­‐productive	   (27).	   In	   a	   large	   survey,	   Talley	   et	   al.	   used	   self-­‐report	  questionnaires	   based	   on	  Manning	   criteria	   to	   diagnose	   IBS	   and	   found	   that	   IBS	  patients	   utilized	   health	   care	   at	   almost	   double	   the	   cost	   compared	   to	   persons	  without	   IBS	  (28).	   In	  a	  survey	   that	  diagnosed	   IBS	  using	   the	   less	   inclusive	  Rome	  criteria,	  Longstreth	  et	  al.	  estimated	  the	   increase	   in	  health	  care	  costs	  associated	  with	   IBS	   to	   be	   51%	   (29).	   The	   severity	   of	   symptoms	   was	   also	   positively	  correlated	  with	  an	  increase	  in	  health	  care	  costs.	  In	  2007,	  the	  mean	  annual	  direct	  health	  care	  costs	  in	  the	  US	  were	  estimated	  at	  $5,049	  per	  treatment	  seeking	  IBS	  patient	   (30).	  Given	   the	  high	  prevalence	  of	   IBS,	   estimated	  at	  10%,	   this	   leads	   to	  large	  costs	   for	   society.	   In	  Finland,	   IBS	  has	  been	  estimated	   to	  account	   for	  up	   to	  5%	  of	  the	  national	  outpatient	  and	  pharmacological	  expenditures	  (31).	  
1.2 DIETARY	  AND	  PHARMACOLOGICAL	  TREATMENTS	  The	   American	   College	   of	   Gastroenterology	   published	   a	   review	   of	  pharmacological	  and	  dietary	  treatments	  for	  IBS	  in	  2009	  (32).	  The	  use	  of	  dietary	  adjustments,	   dietary	   fiber,	   bulking	   agents,	   laxatives,	   antispasmodic	   agents,	  antidiarrheals,	  or	  probiotics,	  was	  considered	  to	  have	  weak	  scientific	  support	  and	  questionable	   beneficial	   effects.	   5HT3	   receptor	   antagonists	   (alosetron),	   5HT4	  receptor	   agonists	   (tegaserod),	   selective	   C-­‐2	   chloride	   channel	   activators	  (lubiprostone),	   and	   antidepressant	   (tricyclics	   and	   selective	   serotonin	   reuptake	  inhibitors)	   had	   moderate	   to	   good	   quality	   of	   evidence	   of	   beneficial	   effects.	  Alosetron	  targets	  diarrhea	  while	  tegaserod	  and	  lubiprostone	  target	  constipation,	  and	  all	  three	  drugs	  have	  primarily	  shown	  effect	  on	  female	  IBS	  patients.	  However,	  alosetron	  and	   tegaserod	  have	  been	  withdrawn	   from	   the	  US	  market	  because	  of	  adverse	  side	  effects.	  Alosetron	  has	  since	  then	  been	  reintroduced	  in	  the	  US	  under	  restricted	   use	   for	   females	   with	   severe	   diarrhea.	   Antidepressants	   have	   been	  shown	  to	  relieve	  global	  IBS	  symptoms	  and	  abdominal	  pain.	  Antibiotics	  have	  also	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been	   studied	   and	   show	   global	   improvement	   of	   IBS	   with	   moderate	   quality	   of	  evidence	  (32).	  	  Hence,	  there	  are	  a	  few	  pharmacological	  therapies	  that	  have	  moderate	  to	  strong	  support	  for	  a	  beneficial	  effect	  in	  IBS.	  However,	  there	  seem	  to	  be	  no	  studies	  that	  show	   long-­‐term	  beneficial	  effects	  after	  pharmacological	   treatment.	  The	   longest	  follow	  up-­‐periods	   that	   have	   been	  noted	   in	   the	   literature	   are	   up	   to	   four	  weeks	  (33-­‐39).	   During	   follow-­‐up	   periods,	   the	   effects	   of	   tegaserod	   (37)	   and	   alosetron	  (33-­‐36)	   quickly	   subside	   while	   the	   effects	   of	   fluoxetine	   (38)	   and	   lubiprostone	  (39)	  seem	  to	  be	  sustained.	  However,	  a	  four-­‐week	  follow-­‐up	  period	  is	  not	  enough	  to	  draw	  any	   conclusions	   about	   long-­‐term	  effects	   of	   fluoxetine	   or	   lubiprostone.	  One	  exception	  is	  the	  antibiotic	  rifaximin.	  In	  one	  study	  about	  32%	  of	  patients	  in	  the	  rifaximin	  group	  reported	  adequate	  relief	  of	  global	  IBS	  symptoms	  compared	  to	  about	  25%	  in	  the	  placebo	  group	  three	  months	  after	  treatment	  (40).	  Notably,	  the	   proportion	   of	   patients	   in	   the	   rifaximin	   group	   reporting	   adequate	   relief	   at	  post-­‐treatment	  was	  almost	  50%.	  In	   summary,	   it	   seems	   that	   most	   pharmacological	   treatments	   with	   adequate	  scientific	  evidence	  for	  effect	  in	  IBS	  need	  to	  be	  used	  continuously	  for	  effect.	  With	  the	   exception	   of	   rifaximin,	   these	   treatments	   have	   side	   effects,	   leading	   to	   the	  withdrawal	  of	  tegaserod	  and	  alosetron	  (32).	  However,	  rifaximin	  is	  not	  available	  for	  prescription	  for	  IBS	  yet	  and	  seems	  to	  have	  a	  declining	  effect	  over	  time	  (40).	  
1.3 BIOLOGICAL	  PROCESSES	  ASSOCIATED	  WITH	  SYMPTOMS	  
1.3.1 GASTROINTESTINAL	  MOTILITY	  Since	  IBS	  patients	  display	  altered	  bowel	  habits,	  much	  research	  has	  been	  devoted	  to	  find	  disturbances	  in	  the	  gut	  motility.	  Many	  findings	  indicate	  altered	  function	  along	   the	  GI	   tract	   in	   IBS	  patients.	   In	   the	  upper	  GI	   tract	  and	  small	  bowel,	   these	  include	  contractions	  in	  the	  esophagus,	  delayed	  gastric	  emptying,	  longer/shorter	  migrating	  motor	  complex	   intervals	   in	  the	  small	  bowel	   in	  constipation/diarrhea	  predominant	   patients,	   and	   delayed/accelerated	   small	   bowel	   transit	   in	  constipation/diarrhea	   predominant	   patients	   (41).	   However,	   none	   of	   these	  findings	  have	  been	  consistent	  between	  IBS	  patients	  or	  studies	  (41).	  In	  the	  large	  bowel	   the	  most	   consistent	   finding	   is	   a	  prolonged	  and	   increased	  motor	   activity	  after	  ingestion	  of	  nutrition	  (41).	  The	  gut	  motility	  has	  also	  been	  found	  to	  be	  reactive	  to	  change	  in	  emotional	  state.	  In	  a	  series	  of	  multiple	  case	  studies	  during	  the	  1940s,	  Almy	  et	  al.	  used	  different	  methods	   to	   induce	   emotional	   distress	   in	   subjects	  with	   and	  without	   functional	  bowel	  disturbances	  and	  observed	  changes	   in	  colonic	  motility.	   In	  the	  first	  study	  (42),	   seven	   healthy	   males	   were	   subjected	   to	   induction	   of	   headache	   by	  compression	  of	  the	  head.	  After	  a	  while	  all	  subjects	  showed	  signs	  of	  stress,	  such	  as	  pallor,	  sweating,	  heightened	  blood	  pressure,	  or	  by	  verbal	  description.	  These	  responses	  were	   accompanied	  by	  heightened	   colonic	  motility	   and	  engorgement	  of	  the	  mucosa.	  In	  the	  second	  study	  (43),	  several	  methods	  of	  induction	  of	  stress	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by	   physical	   threat	   were	   used	   in	   healthy	   subjects,	   including	   cold	   pain	  (submerging	  the	  hand	  in	  ice	  water),	  headache,	  and	  induced	  hypoglycemia.	  This	  study	  also	  included	  verbal	  induction	  of	  stress.	  Individual	  life	  situations	  that	  were	  associated	   with	   emotional	   distress,	   e.g.	   one	   subject’s	   failure	   to	   discipline	   his	  rebellious	  son,	  were	  discussed	  with	  the	  subjects.	  One	  subject	  was	  also	  deceived	  to	  believe	  that	  signs	  of	  cancer	  had	  been	  found	  during	  examination	  of	  the	  colon.	  In	   almost	   all	   cases	  where	   the	   subjects	   responded	  with	   stress	   reactions	   to	   the	  physical	  or	  verbal	  stimuli,	   increases	  in	  colonic	  motility	  were	  observed.	  The	  last	  two	   studies	   included	   subjects	   with	   functional	   constipation	   (44)	   and	   IBS	   with	  diarrhea,	  constipation,	  or	  alternating	  predominance	  (45).	  Again,	  when	  stressful	  stimuli	  were	  presented	  and	  subjects	  reacted	  with	  stress,	  increased	  motility	  was	  observed.	  The	  researchers	  noted	  that	  the	  changes	  in	  motility	  related	  to	  stress	  in	  the	   subjects	   with	   functional	   constipation	   were	   quantitatively	   similar	   to	   the	  changes	  previously	  observed	  in	  healthy	  individuals	  (44).	  Later	   studies	   have	   confirmed	   the	   impact	   of	   stress	   on	   the	   GI	   system,	   including	  decreased	  mouth	  to	  cecum	  transit	  time	  (46),	  increased	  colonic	  motility	  (47,	  48),	  delayed	  gastric	  emptying	  (49,	  50),	  and	  alteration	  in	  duodenal	  motility	  (49).	  
1.3.2 HYPERSENSITIVITY	  While	  disturbed	  motility	  patterns	  may	  explain	   the	  altered	  bowel	  habits	   in	   IBS,	  they	   do	   not	   explain	   the	   pain	   experienced	   by	   IBS	   patients.	   Visceral	  hypersensitivity,	   i.e.	   lowered	   discomfort	   threshold	   to	   visceral	   stimulation,	   is	  currently	   considered	   one	   of	   the	   most	   important	   factors	   in	   IBS	   and	   has	   been	  extensively	   studied.	   Increased	   sensitivity	   to	   stimulation	   has	   primarily	   been	  observed	   in	   the	   colon	   but	   also	   in	   the	   esophagus,	   stomach,	   and	   small	   intestine	  (41).	  Similarly	   to	   the	   findings	  regarding	  gut	  motility,	  hypersensitivity	  has	  been	  found	  to	  increase	  in	  response	  to	  stress.	  In	  one	  study,	  stress	  induced	  by	  listening	  to	  conflicting	  types	  of	  music	  (folk	  music	  in	  one	  ear	  and	  rock	  and	  roll	  in	  the	  other)	  produced	   stronger	   unpleasantness	   and	   subjectively	   rated	   intensity	   of	   visceral	  stimulation	  in	  IBS	  patients	  than	  in	  controls	  (51).	  In	  another	  study,	  both	  physical	  stress	  (hand	  in	  ice	  water)	  and	  psychological	  stress	  (conflicting	  music)	  produced	  decreased	  perceptual	  and	  pain	  thresholds	  for	  visceral	  stimulation	  in	  IBS	  patients	  but	  not	  in	  controls	  (52).	  In	  several	  studies,	  hypersensitivity	  has	  also	  been	  found	  to	  increase	  after	  intake	  of	  nutrition	  (41).	  Bloating,	   a	   symptom	   experienced	   by	   a	   majority	   of	   IBS	   patients	   (53),	   has	   also	  been	  associated	  with	  hypersensitivity.	  Bloating	  has	  not	  been	  linked	  to	  increased	  volumes	   of	   abdominal	   gas	   (54)	   but	   there	   is	   much	   evidence	   for	   a	   delayed	   gas	  transit	  time	  associated	  with	  bloating	  (55).	  However,	  delayed	  transit	  time	  seems	  to	   be	   more	   correlated	   with	   measurable	   abdominal	   distension	   than	   with	   the	  bloating	  sensation	  (56-­‐58).	  In	  one	  study,	  only	  50%	  of	  IBS	  patients	  who	  reported	  bloating	   showed	   abdominal	   distension	   (59).	   Patients	  who	   experience	   bloating	  without	   distension	   have	   been	   shown	   to	   have	   increased	   hypersensitivity	  compared	   to	   patients	  who	   experience	   both	   symptoms	   (60).	   Furthermore,	   in	   a	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study	   of	   pharmacological	   treatment	   that	   targeted	   gas	   production,	   decrease	   in	  bloating	  was	  only	  seen	  in	  patients	  without	  hypersensitivity	  (61).	  
1.4 THE	  ROLE	  OF	  STRESS	  Although	  several	  studies	  suggest	  an	  organic	  dysfunction	  in	  IBS,	  such	  as	  delayed	  transit	  of	  nutrition	  and	  gas,	  there	  is	  convincing	  evidence	  for	  stress	  as	  a	  cause	  of	  IBS	   symptomatology.	   Here,	   stress	   is	   defined	   as	   ”an	   acute	   threat	   to	   the	  homeostasis	   of	   an	   organism,	   real	   (physical)	   or	   perceived	   (psychological)	   and	  posed	  by	   events	   in	   the	  outside	  world	  or	   from	  within,	   [which]	   evokes	   adaptive	  responses	  that	  serve	  to	  defend	  the	  stability	  of	   the	   internal	  environment	  and	  to	  ensure	   the	   survival	   of	   the	   organism”	   (62	   p.	   G519).	   Stress	   has	   been	   shown	   to	  affect	   both	   motility	   and	   hypersensitivity,	   presumably	   causing	   altered	   bowel	  habits	  and	  sensations	  of	  pain	  and	  bloating.	  Indeed,	  IBS	  is	  often	  referred	  to	  as	  a	  “stress-­‐related	  disorder”,	  but	  from	  where	  does	  this	  stress	  emanate?	  A	  number	  of	  studies	  (63-­‐67)	  have	  investigated	  the	  impact	  of	  daily	  stressors	  on	  IBS	  symptoms.	  While	   some	   studies	   point	   toward	   a	   causative	   effect	   of	   daily	   stressors	   on	   IBS	  symptoms	  the	  most	  consistent	  finding	  is	  a	  reciprocal	  relationship	  (67).	  Thus,	  the	  primary	  source	  of	  symptom-­‐causing	  stress	  is	  probably	  related	  to	  daily	  stressors	  only	   to	   a	   limited	   extent.	   Below,	   the	   evidence	   for	   psychiatric	   factors	   and	  symptom-­‐related	  fear	  as	  potential	  sources	  of	  stress	  is	  reviewed.	  
1.4.1 PSYCHIATRIC	  FACTORS	  	  Population-­‐based	   studies	   have	   investigated	   the	   prevalence	   of	   psychiatric	  disorders	  in	  IBS	  patients	  compared	  to	  normal	  controls.	  All	  studies	  reviewed	  here	  used	  random	  sampling	  except	  one	  that	  compared	  all	  IBS	  patients	  within	  a	  health	  maintenance	   organization	   to	   matched	   controls	   (68).	   In	   these	   studies,	   the	  prevalence	   of	   the	   following	   disorders	   was	   larger	   among	   IBS	   patients	   than	  normal	  controls:	  generalized	  anxiety	  disorder	  (68,	  69),	  depression,	  (68,	  70,	  71),	  panic	  disorder	  (19),	  panic	  attacks	  (68),	  somatization	  disorder	  (68,	  71),	  obsessive	  compulsive	  disorder	  (71),	  stress	  reaction	  (68),	  impaired	  mental	  health	  (72),	  life	  time	   anxiety	   or	   mood	   disorders	   (73),	   and	   any	   psychiatric	   disorder	   (74).	   The	  highest	   population	   prevalences	   of	   psychiatric	   disorders	   in	   IBS	  were	   found	   for	  lifetime	   anxiety	   or	   mood	   disorders	   (50%;	   73),	   depression	   (30%;	   68),	   stress	  reaction	  (17%;	  68),	  and	  generalized	  anxiety	  disorder	  (16%;	  69).	  The	  prevalence	  of	  IBS	  has	  also	  been	  investigated	  among	  patients	  diagnosed	  with	  a	   psychiatric	   disorder.	   In	   a	   recent	   study	   including	   357	   psychiatric	   patients,	  higher	   frequencies	   than	   population	   prevalence	   of	   IBS	   were	   found	   in	   patients	  with	  generalized	  anxiety	  disorder	  (26%),	  panic	  disorder	  (22%),	  and	  depression	  (25%)	  (75).	  Another	  study	  examined	  the	  prevalence	  of	  IBS	  in	  patients	  diagnosed	  with	  obsessive-­‐compulsive	  disorder	  and	  found	  that	  35%	  of	  patients	  fulfilled	  IBS	  diagnostic	  criteria	  compared	  to	  3%	  of	  matched	  controls	  (76).	  A	  review	  of	  studies	  published	   before	   2003	   reported	   increased	   prevalence	   of	   IBS	   in	   patients	   with	  depression	   (27-­‐29%),	   panic	   disorder	   (17%-­‐46%),	   and	   generalized	   anxiety	  disorder	  (37%)	  (76).	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IBS	  patients	  have	  also	  been	  found	  to	  have	  an	  increased	  need	  for	  social	  approval	  (77),	   a	  more	   submissive	   interpersonal	   style	   (78),	   and	   feelings	  of	   interpersonal	  inferiority	  (79)	  compared	  to	  healthy	  controls.	  In	  IBS	  patients	  a	  cognitive	  style	  of	  negative	   thinking	   predicts	   more	   suffering	   related	   to	   IBS	   symptoms	   (80)	   and	  general	  worry	  and	  anxiety	  is	  positively	  correlated	  with	  pain	  severity	  (81).	  High	  levels	  of	  neuroticism	  have	  also	  been	  found	  to	  be	  predictive	  of	  an	  IBS	  diagnosis	  (82).	  
1.4.2 SYMPTOM-­‐RELATED	  FEAR	  AND	  AVOIDANCE	  BEHAVIORS	  Pertaining	   to	   the	   previous	   definition	   of	   stress,	   symptom-­‐related	   fear	   is	   the	  process	  where	  a	  symptom	  or	  symptom-­‐related	  stimuli	   is	  perceived	  as	  an	  acute	  threat	  to	  the	  homeostasis.	  In	  2001,	  Mayer	  et	  al.	  suggested	  that	  conditioned	  fear	  of	   symptom-­‐related	  stimuli	   could	  be	  an	   important	  characteristic	  of	   IBS	   (83).	   It	  was	   hypothesized	   that	   most	   IBS	   patients	   have	   had	   negative	   experiences	   of	  symptoms,	   such	   as	   intense	   abdominal	   pain	   or	   nearly	   losing	   control	   of	   their	  bowel,	   that	  have	  been	  preceded	  by	  neutral	  stimuli.	  These	  neutral	  stimuli	  could	  be	   visceral	   sensations,	   e.g.	   fullness	   or	   urgency,	   and	   contexts	   in	   which	   these	  sensations	  could	  occur,	  e.g.	  time	  of	  day	  or	  after	  food	  intake	  (83).	  	  An	  association	  between	  symptom-­‐related	  stimuli	  and	  fear	  in	  IBS	  has	  interesting	  implications,	  since	  both	  unconditioned	  (84)	  and	  conditioned	  (85)	  fearful	  stimuli	  draw	   our	   attention.	   Conditioned	   fear	   of	   symptom-­‐related	   stimuli	   should	  therefore	   increase	   IBS	   patients’	   focus	   on	   these	   stimuli.	   Several	   studies	   have	  confirmed	  this.	   IBS	  patients	  show	   increased	  attention	   to	  pain	  words	  compared	  to	   normal	   controls	   and	   level	   of	   attention	   is	   positively	   correlated	  with	   somatic	  complaints	   (86).	   Moreover,	   IBS	   patients	   remember	   (87)	   and	   recognize	   (88)	  words	  describing	  GI	  sensations	  better	  than	  controls,	  and	  they	  are	  more	  attentive	  to	   subliminally	  presented	  words	   that	  describe	  GI	   sensations	   (89).	   IBS	  patients	  also	  report	  that	  they	  are	  more	  vigilant	  towards	  bodily	  symptoms	  than	  controls	  (90).	  Catastrophic	  thinking	  about	  pain	  is	  also	  linked	  to	  more	  severe	  pain	  in	  IBS	  patients	  (91,	  92).	  Mayer	   et	   al.	   further	   suggested	   that	   the	   hypersensitivity	   towards	   visceral	  sensations,	  such	  as	  pain	  and	  bloating,	  may	  be	  a	  function	  of	  this	  conditioned	  fear	  (83).	  The	  close	  association	  between	  hypersensitivity	  and	  fear	  of	  IBS	  sensations	  has	  been	  confirmed	  in	  brain	   imaging	  studies.	  During	  painful	  rectal	  stimulation,	  IBS	   patients	   show	   increased	   activity	   in,	   among	   other	   regions,	   the	   anterior	  cingulate	  cortex	  (ACC;	  93,	  94).	  The	  ACC	  has	  been	  suggested	  to	  play	  a	  part	  in	  the	  affective	  dimension,	  e.g.	   fear,	  of	  pain	  (95).	   In	   two	  studies,	  decrease	   in	  pain	  has	  also	  been	  associated	  with	  decrease	  in	  ACC	  activity.	  Naliboff	  et	  al.	  used	  repeated	  exposure	   to	   decrease	   rectal	   sensitivity	   in	   IBS	   patients	   and	   observed	   lower	  activity	  in	  the	  ACC	  while	  activity	  in	  the	  brain	  regions	  that	  process	  visceral	  input	  did	  not	  change	  (96).	  Lackner	  et	  al.	  reported	  that,	  following	  cognitive	  therapy,	  IBS	  patients	  showed	  decreased	  global	  pain	  and	  decreased	  activity	  in	  the	  ACC,	  among	  other	  regions	  (97).	  The	  elevation	  of	  hypersensitivity	  during	  stress	  confirms	  the	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association	  with	  symptom-­‐related	   fear,	  since	  stress	  has	  been	   found	  to	   increase	  the	   orientation	   towards	   threat	   stimuli	   (98).	   Together,	   these	   observations	  suggest	  that	  hypersensitivity	  is	  closely	  linked	  to,	  and	  may	  even	  be	  a	  function	  of,	  a	  negative	  emotional	  valence	  of	  visceral	  sensations.	  	  This	   constitutes	   a	   solid	   foundation	   for	   positive	   feedback	   loops	   between	   stress	  and	   IBS	   symptoms.	   The	   association	   between	   fear	   and	  GI	   sensations	   leads	   to	   a	  decreased	   threshold	   for	   detecting	   these	   sensations.	   Detection	   of	   GI	   sensations	  will	  in	  turn	  induce	  stress,	  because	  of	  the	  same	  fear	  association,	  which	  will	  lead	  to	  further	   vigilance	   towards	   sensations,	   such	   as	   pain	   and	   bloating,	   and	   also	   alter	  motility,	  causing	  constipation	  or	  diarrhea.	  These	  symptoms	  further	  increase	  the	  stress	   and	   consequently	   also	   the	   IBS	   symptoms.	   Situations	   that	   are	   symptom-­‐related	  will	   also	   be	   sources	   of	   stress,	   such	   as	   eating	   or	   being	   far	   away	   from	  a	  restroom.	   The	   increased	   motility	   and	   hypersensitivity	   induced	   by	   intake	   of	  nutrition	   and	   the	   general	   experience	   of	   IBS	  patients	   that	   symptoms	   get	  worse	  after	  eating	  (99)	  may	  even	  be	  a	  stress	  response	  to	  a	  conditioned	  fear	  of	  food.	  A	  natural	   response	   to	   stimuli	   that	   evoke	   fear	   is	   to	  avoid	   them.	  However,	   long-­‐term	  avoidance	  of	  the	  multitude	  of	  stimuli	  that	  could	  potentially	  be	  related	  to	  GI	  symptoms	  may	   actually	   be	   a	   key	  maintaining	   factor	   in	   IBS.	   By	   avoiding	   these	  stimuli,	   IBS	   patients	   cannot	   gain	   new	   experiences	   that	   reduce	   the	   fear	   of	   the	  symptoms	   and	   associated	   stimuli,	   e.g.	   being	   able	   to	   function	   despite	   having	  symptoms,	   maintaining	   control	   over	   bowels	   despite	   urgency,	   or	   experiencing	  milder	   symptoms	   than	   expected	   after	   ingestion	   of	   certain	   foods.	   Furthermore,	  avoiding	   social	   or	   work-­‐related	   situations	   when	   experiencing	   symptoms	   can	  cause	   social	   isolation	   and	  disability.	   This	   increases	   general	   stress	   and	   reduces	  quality	  of	  life,	  thereby	  strengthening	  the	  negative	  valence	  of	  symptoms.	  Several	   studies	   have	   confirmed	   the	   importance	   of	   symptom-­‐related	   fear	   and	  associated	   behaviors	   in	   IBS.	   In	   a	   university	   sample,	   fear	   of	   IBS	   symptoms	   and	  fear-­‐related	  behaviors	  have	  been	  found	  to	  be	  significantly	  more	  associated	  with	  IBS	  diagnosis	   than	  general	  worry,	  anxiety	   sensitivity,	  or	  neuroticism	  (100).	  An	  IBS	  diagnosis	  has	  also	  been	  associated	  with	  a	  desire	  to	  avoid	  bodily	  sensations	  (90).	  The	  level	  of	  symptom	  avoidance	  and	  symptom	  controlling	  behaviors	  is	  also	  related	   to	   severity	   of	   IBS	   symptoms	   and	  negative	   evaluation	   of	   IBS	   symptoms	  (101).	   Impaired	   physical	   functioning	   and	   dysfunctional	   eating	   together	   with	  number	  of	  days	  in	  bed	  and	  phone	  calls	  to	  the	  physician	  because	  of	  GI	  symptoms	  also	   predict	   IBS	   symptom	   severity	   (102).	   Labus	   et	   al.	   developed	   the	   visceral	  sensitivity	   index	   (VSI),	   aimed	   at	  measuring	   “gastrointestinal	   symptom-­‐specific	  anxiety”	   (103).	   GI	   symptom-­‐specific	   anxiety	   is	   a	   concept	   that	   involves	   the	  cognitive,	  affective,	  attentional,	  and	  behavioral	  dimensions	  relating	  to	  fear	  of	  IBS	  symptom	   and	   associated	   situations.	   In	   a	   validation	   study	   of	   the	   VSI	   in	   an	  undergraduate	   sample	   it	  was	   found	   to	   discriminate	   between	   students	  without	  IBS	  (lowest	  score),	   students	  with	   IBS	  who	  had	  not	  sought	  health	  care	   for	   their	  symptoms	   (intermediate	   score),	   and	   students	   with	   IBS	   symptoms	   who	   had	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sought	   help	   for	   their	   symptoms	   (highest	   score).	   The	   VSI	   was	   also	   the	   only	  measure	   that	  predicted	  presence	  of	  an	   IBS	  diagnosis	  compared	   to	  measures	  of	  anxiety	   sensitivity,	   anxiety,	   depression,	   and	   neuroticism	   (104).	   In	   a	   sample	   of	  IBS	   patients,	   the	   VSI	   was	   found	   to	   be	   the	   strongest	   predictor	   of	   GI	   symptom	  severity,	   compared	   to	   presence	   of	   other	   functional	   GI	   disorders,	   anxiety,	  depression,	   and	   gender	   and	  was	   also	   negatively	   correlated	  with	   quality	   of	   life	  (105).	  
1.5 PSYCHOLOGICAL	  TREATMENTS	  Several	  psychological	  treatments	  targeting	  different	  sources	  of	  stress	  in	  IBS	  have	  been	   developed	   and	   evaluated.	   Below,	   studies	   investigating	   the	   effects	   of	   the	  major	   approaches	   are	   summarized.	   These	   approaches	   include	   psychodynamic	  therapy,	   hypnotherapy,	   cognitive	   behavioral	   therapies,	   and	   minimal	   contact	  cognitive	  behavioral	  therapies.	  
1.5.1 PSYCHODYNAMIC	  THERAPY	  The	   first	   randomized	   controlled	   trial	   of	   a	   psychological	   treatment	   for	   IBS,	  published	  in	  1983,	  was	  conducted	  in	  Sweden	  and	  evaluated	  the	  effects	  of	  short-­‐term	  (10	  sessions)	  psychodynamic	  therapy	  for	  IBS	  (106).	  The	  treatment	  focused	  on	   coping	   with	   stress	   and	   emotional	   problems.	   In	   accordance	   with	   a	  psychodynamic	   theory	   of	   psychosomatic	   disorders	   (107),	   the	   therapy	   was	  mainly	   supportive	   and	   was	   not	   focused	   on	   unconscious	   processes	   or	   other	  psychoanalytical	   concepts.	   A	   psychodynamically	   informed	   therapy	   has	  subsequently	   been	   evaluated	   in	   two	   additional	   studies	   (108,	   109).	   These	  treatments	   were	   focused	   on	   emotional	   problems	   of	   the	   study	   participants,	  primarily	  relationship	  problems.	  	  The	   outcomes	   in	   these	   three	   studies	   of	   psychodynamic	   therapy	  were	   positive	  with	  improvements	  both	  on	  both	  psychological	  measures	  and	  in	  IBS	  symptoms,	  with	  the	  exception	  of	  the	  last	  study	  that	  did	  not	  show	  long-­‐term	  effects	  on	  pain	  compared	  to	  routine	  care	  (109).	  
1.5.2 HYPNOTHERAPY	  Hypnotherapy	  for	  IBS	  is	  aimed	  at	  gaining	  increased	  control	  over	  the	  gut	  and	  also	  includes	  ego-­‐strengthening	  and	  confidence-­‐building	  interventions	  (110).	  Several	  studies	   have	   evaluated	   hypnotherapy	   for	   IBS	   and	   in	   a	   recent	   review	   it	   was	  concluded	   that	   60%-­‐70%	   of	   IBS	   patients	   gain	   substantial	   symptom	  improvement	   from	  hypnotherapy	  (111).	  After	  hypnotherapy,	   IBS	  patients	  have	  shown	   reductions	   in	   negative	   thoughts	   about	   their	   gut	   function	   (112)	   and	   a	  reduced	   sensory	   and	   motor	   response	   after	   intake	   of	   nutrition	   (113).	   These	  results	   point	   towards	   a	   reduction	   of	   fear	   of	   GI	   symptoms	   as	   a	   result	   of	  hypnotherapy.	  
1.5.3 COGNITIVE	  BEHAVIORAL	  THERAPIES	  Within	  the	  cognitive	  behavioral	  field	  there	  have	  been	  many	  different	  approaches	  to	   treating	   IBS.	   In	   1987,	   Blanchard’s	   group	   published	   their	   first	   studies	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investigating	   the	   effects	   of	   a	   multicomponent	   treatment,	   including	   relaxation	  training,	   thermal	   biofeedback,	   and	   training	   in	   stress-­‐coping	   strategies	   on	   IBS	  (114,	   115).	   In	   these	   studies	   about	   60%	   of	   the	   patients	   showed	   clinically	  significant	   improvement	   and	   these	   improvements	   were	   maintained	   over	   a	   2-­‐	  and	  4-­‐year	  period	  (116,	  117).	  The	  same	  group	  also	  performed	  a	  small	  study	  with	  only	  5	  IBS	  patients,	  investigating	  bowel	  sound	  biofeedback	  with	  a	  60%	  response	  rate	   (118).	   Later	   studies	   showed	  beneficial	   effects	   of	   relaxation	   training	   (119)	  and	  relaxation	  meditation	  (120)	  on	  IBS	  with	  50%-­‐60%	  response	  rates.	  However,	  in	  1992	  the	  Blanchard	  group	  published	  a	  study	  comparing	  the	  multicomponent	  treatment	  with	   an	   attention	   control	   condition	   and	   did	   not	   find	   any	   significant	  differences	  in	  treatment	  effect	  (121).	  In	   1994,	   the	   Blanchard	   group	   published	   a	   study	   that	   only	   included	   cognitive	  interventions	   and	   the	   treatment	   was	   labeled	   cognitive	   therapy	   (122).	   The	  rationale	   for	   focusing	   on	   distorted	   and	   maladaptive	   cognitions	   was	   the	   large	  prevalence	  of	  anxiety	  and	  mood	  disorders	  in	  IBS.	  These	  psychological	  problems,	  primarily	  anxiety,	  were	  hypothesized	  to	  underlie	  the	  IBS	  symptoms.	  A	  treatment	  that	   successfully	   targeted	   these	   psychological	   problems	   should	   therefore	   also	  relieve	   the	   IBS	   symptoms	   (122).	   The	   treatment	   was	   evaluated	   in	   two	   further	  studies	   and	   showed	   superiority	   to	   an	   attention	   control	   condition	   (123)	   and	  similarity	  in	  effectiveness	  whether	  administered	  individually	  or	  in	  group	  (124).	  In	   these	   studies,	   55%-­‐80%	   of	   the	   patients	   showed	   a	   clinically	   significant	  improvement	   after	   cognitive	   therapy.	   However,	   the	   studies	   were	   small,	  including	  only	  10-­‐11	  patients	   in	   the	   treatment	   conditions.	   In	  2007,	   the	   largest	  trial	   by	   the	   Blanchard	   group	  was	   published,	   including	   210	   IBS	   patients	   (125).	  The	   study	   compared	   group	   cognitive	   therapy	   (n=120)	   with	   attention	   control	  (n=46)	   and	   symptom	  monitoring	   (n=44),	  with	  discouraging	   results.	   The	   group	  cognitive	  therapy	  was	  not	  superior	  to	  the	  attention	  control	  in	  terms	  of	  symptom	  reduction	   and	   treatment	   effects	  were	   considerably	   lower	   than	   in	   the	   previous	  studies.	  Toner	  et	  al.	  published	  a	  study	  of	  group	  CBT	  for	  IBS	  in	  1998	  (126).	  The	  authors	  argued	   that	   previous	   studies	   of	   cognitive	   behavioral	   therapies	   for	   IBS	  had	  not	  been	   based	   on	   models	   specific	   for	   IBS	   but	   rather	   on	   general	   models	   of	  psychopathology	   relating	   mainly	   to	   anxiety	   and	   depression.	   In	   contrast,	   their	  treatment	   was	   based	   on	   a	   model	   developed	   by	   Sharpe	   et	   al.	   (127),	   which	  stresses	  the	  way	  the	  IBS	  patients	  think	  about	  their	  symptoms.	  Patients	  who	  are	  convinced	  that	  their	  symptoms	  are	  signs	  of	  serious	  illness	  become	  more	  aware	  of	   their	   symptoms,	   entering	   into	   a	   vicious	   circle.	   These	   thoughts	   cause	  dysfunctional	   behaviors	   such	   as	   excessive	   treatment	   seeking	   or	   avoidance	   of	  symptom	  provoking	  activities.	  These	  behaviors	  make	  it	  harder	  for	  the	  patient	  to	  identify	   what	   situations	   actually	   contribute	   to	   the	   stress	   that	   creates	   the	  symptoms.	   Besides	   targeting	   these	   mechanisms,	   the	   treatment	   also	   included	  pain	   management	   techniques	   like	   distraction	   and	   relaxation.	   Other	   themes,	  deemed	   to	   be	   important	   in	   IBS	   (128),	   included	   lack	   of	   assertiveness,	   need	   for	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social	   approval,	   shame	  over	   symptoms,	  perfectionism,	  and	   lack	  of	   self-­‐efficacy.	  Although	   this	   treatment	   was	   designed	   specifically	   for	   IBS,	   it	   failed	   to	   show	  superiority	   to	   an	   attention	   control	   condition	   (126).	   In	   2003,	   Drossman	   et	   al.	  published	   a	   large-­‐scale	   study	   that	   compared	   the	   same	   treatment	   in	   individual	  format	  (n=144)	  with	  education	  (n=71)	  (129).	  This	  study	  also	  failed	  to	  show	  that	  the	   treatment	   was	   more	   effective	   than	   an	   attention	   control	   in	   reducing	   IBS	  symptoms.	  Boyce	   et	   al.	   published	   a	   pilot	   study	   of	   a	   CBT	   including	   relaxation	   training,	  breathing	  training,	  cognitive	  restructuring,	  assertiveness	   training,	  and	  problem	  solving	   (130).	   This	   seems	   to	   be	   the	   first	   study	   that	   also	   explicitly	   stated	   that	  exposure	  exercises	  were	  used.	  These	  were	  aimed	  at	  reducing	  negative	  thoughts	  and	  fear	  associated	  with	  IBS	  symptoms,	  by	  graded	  exposure	  to	  feared	  situations	  and	   behavioral	   testing	   of	   negative	   predictions	   about	   the	   impact	   of	   IBS	  symptoms.	   A	   dysfunctional	   cognitive	   style	   was	   hypothesized	   to	   underlie	   this	  catastrophic	   interpretation	   of	   IBS	   symptoms	   and	   the	   comorbid	   psychiatric	  disorders.	   The	   pilot	   trial	   produced	   promising	   results.	   However,	   a	   later	   study	  from	  2003	  comparing	  the	  treatment	  (n=35)	  with	  relaxation	  training	  (n=35)	  and	  routine	   care	   (n=33)	   did	   not	   show	   any	   differential	   effects	   (131).	   The	   authors	  concluded	   that	   the	   effect	   of	   any	   psychological	   treatment	   was	   most	   likely	   the	  result	  of	  common	  factors	  such	  a	  trusting	  relationship	  and	  hope	  of	  improvement.	  The	   fact	   that	   the	   study	  had	  been	  underpowered	  was	  discarded	  by	   the	  authors	  using	  post-­‐hoc	  reasoning.	  Above,	   cognitive	  behavioral	   therapies	   that	  have	  been	  evaluated	   in	  at	   least	   two	  studies	   have	   been	   reviewed.	   There	   have	   been	   additional	   solitary	   studies	  investigating	  multicomponent	   CBT	  protocols,	   including	   e.g.	   relaxation	   training,	  cognitive	   restructuring,	   and	   problem	   solving	   (but	   not	   biofeedback).	   There	   are	  mixed	  results	  from	  these	  studies.	  Five	  studies	  have	  shown	  marked	  effects	  on	  IBS	  symptom	   (132-­‐136),	   while	   two	   have	   failed	   to	   show	   substantial	   effects	   on	  symptoms	   compared	   to	   controls	   (137,	   138)	   and	   in	   one	   patients	   experienced	  symptom	  relapse	  during	  study	  follow-­‐up	  (139).	  In	   a	   meta-­‐analysis	   from	   2004	   on	   psychodynamic	   and	   cognitive	   behavioral	  therapies	   for	   IBS,	   Lackner	   et	   al.	   concluded	   that	   the	   pooled	   number	   needed	   to	  treat	   to	  gain	  one	  clinically	   significant	   improvement	  was	  2	   (140).	  However,	   the	  meta-­‐analysis	   did	   not	   include	   the	   three	   studies	   that	   had	   failed	   to	   show	  superiority	   of	   cognitive	   therapy	   or	   multicomponent	   CBT	   to	   attention	   control	  (125,	  129,	  131).	  Ford	  et	  al.	  published	  a	  more	  recent	  meta-­‐analysis	  and	  included	  the	   Boyce	   et	   al.	   (131)	   and	  Drossman	   et	   al.	   (129)	   studies.	   They	   found	   that	   the	  number	  needed	  to	  treat	  with	  CBT	  was	  3	  (141).	  But	  it	  was	  also	  concluded	  that	  if	  the	   three	   early	   studies	   of	   cognitive	   therapy	   that	   had	   been	   performed	   by	   the	  Blanchard	   group	   (122-­‐124)	   were	   removed	   from	   the	   analysis,	   the	   beneficial	  effect	  of	  CBT	  on	  IBS	  symptoms	  disappeared.	  Notably,	  the	  study	  by	  Blanchard	  et	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al.	   (125),	   which	   showed	   poor	   effect	   of	   the	   cognitive	   intervention,	   was	   not	  included	  in	  this	  meta-­‐analysis	  either.	  
1.5.4 MINIMAL	  CONTACT	  CBT	  TREATMENTS	  Despite	   the	   promising	   results	   in	   many	   trials	   during	   30	   years	   of	   research,	  psychological	   treatments	   have	   not	   become	   widely	   available	   for	   IBS	   patients	  (142).	  Efforts	  to	  develop	  more	  accessible	  treatments	  have	  been	  made,	  where	  the	  therapist	  time	  is	  minimized	  and	  patients	  are	  given	  self-­‐help	  material	  that	  covers	  the	   content	   of	   treatment.	   Heitkemper	   et	   al.	   combined	   a	   multicomponent	   self-­‐help	   book	  with	   one	   session	   led	   by	   a	   nurse	   but	   demonstrated	   small	   effects	   on	  symptoms	   (136).	   Robinson	   et	   al.	   used	   an	   informational	   self-­‐help	   book	   and	   a	  series	  of	  focus	  group	  meetings,	  with	  little	  effect	  on	  IBS	  symptoms	  (143).	  Sanders	  et	  al.	  used	  a	  multicomponent	  self-­‐help	  book,	  but	  did	  not	  include	  any	  therapeutic	  support	  and	  the	  study	  showed	  small	  effects	  on	  IBS	  symptoms	  (144).	  	  Lackner	  et	  al.	  published	  a	  study	  in	  2008	  comparing	  two	  ways	  to	  administer	  CBT,	  which	   included	   cognitive	   restructuring	   and	   relaxation	   (145).	   Patients	   were	  randomized	   to	   a	   self-­‐help	   treatment	   combined	   with	   4	   sessions	   of	   therapist	  contact,	   to	   a	   complete	   10-­‐session	   therapist	   administered	   treatment,	   or	   to	   a	  waiting	   list	   control.	   The	   study	   found	   similar	   and	   large	   improvements	   in	   IBS	  symptoms	   and	   quality	   of	   life	   in	   both	   treatment	   conditions	   compared	   to	   the	  waiting	   list.	   The	   authors	   concluded	   that	   although	   the	   idea	   of	   low	   intensity	  psychological	   treatments	   for	   IBS	   is	   appealing,	   a	   certain	   amount	   of	   qualified	  therapist	   contact	   is	   probably	   needed	   to	   achieve	   satisfactory	   treatment	   effects.	  Subsequently,	  two	  studies	  that	  used	  telephone	  contact	  to	  support	  the	  patients	  in	  working	   with	   self-­‐help	   material	   were	   published.	   Jarret	   et	   al.	   compared	   usual	  care	   with	   two	   versions	   of	   a	   9-­‐session	   multicomponent	   treatment,	   one	   with	   9	  face-­‐to-­‐face	   sessions	   and	   one	   with	   3	   face-­‐to-­‐face	   sessions	   plus	   6	   telephone	  sessions	   (146).	   Patients	   in	   both	   treatment	   groups	   received	   the	   self-­‐help	   book	  that	  had	  been	  used	   in	   the	  previous	   study	  by	  Heitkemper	  et	  al.	   (136).	  Both	   the	  face-­‐to-­‐face	   and	   telephone	   support	   groups	   showed	   similar	   and	   marked	  improvements	  in	  IBS	  symptoms	  compared	  to	  the	  usual	  care	  group.	  Moss-­‐Morris	  et	   al.	   randomized	   IBS	   patients	   to	   a	   7-­‐week	   treatment	   consisting	   of	   a	  multicomponent	  self-­‐help	  book	  and	  one	  face-­‐to-­‐face	  session	  plus	  two	  telephone	  sessions	   or	   a	   treatment	   as	   usual	   group	   (147).	   Six	  months	   after	   treatment,	   the	  treatment	  group	  showed	  large	  improvements	  in	  IBS	  symptoms	  compared	  to	  the	  treatment	  as	  usual	  group.	  
1.5.5 SUMMARY	  OF	  PSYCHOLOGICAL	  TREATMENTS	  Several	  studies	  have	  evaluated	  the	  effects	  of	  different	  psychological	  approaches	  in	  treating	  IBS.	  The	  support	  for	  psychodynamic	  therapy	  and	  cognitive	  behavioral	  approaches	   is	  mixed,	  with	  some	  studies	  demonstrating	  small	   treatment	  effects	  on	   IBS	   symptoms.	   Hypnotherapy	   seems	   to	   be	   the	   treatment	   that	   most	  consistently	  produces	  positive	  results.	  However,	  although	  a	  pilot	  study	  suggests	  that	  hypnotherapy	  can	  be	  administered	  at	  home	  using	  pre-­‐recorded	  CDs	  (148),	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current	  protocols	  demand	  weekly	  sessions	  with	  a	   trained	  hypnotherapist.	  This	  highlights	   the	   large	   gap	   between	   supply	   and	   demand	   when	   it	   comes	   to	  psychological	   treatments	   for	   IBS.	  With	  a	  10%	  prevalence	  of	   IBS,	  all	  patients	   in	  need	   cannot	   expect	   to	   be	   treated	   by	   professional	   therapists,	   regardless	   of	  treatment	  approach.	  Reducing	  the	  amount	  of	  therapist	  time	  to	  almost	  null	  to	  fix	  the	   treatment	   gap	   has	   not	   been	   a	   successful	   strategy.	   Replacing	   face-­‐to-­‐face	  sessions	   with	   telephone	   contact	   and/or	   reducing	   the	   number	   of	   face-­‐to-­‐face	  sessions	  has	  been	  successful.	  Still,	  face-­‐to-­‐face	  sessions	  require	  travel	  on	  part	  of	  the	   patient	   during	   office	   hours	   and	   telephone	   sessions	   require	   scheduling	   of	  contact,	  also	  during	  office	  hours.	  Symptom-­‐related	   fear	  and	  accompanying	  avoidance	  behaviors	  has	  been	  shown	  to	  be	  the	  most	  important	  predictor	  of	  IBS	  diagnostic	  status,	  compared	  to	  general	  psychological	   distress.	   Yet,	   none	   of	   the	   psychological	   approaches	   described	  above	   have	  made	   symptom-­‐related	   fear	   and	   avoidance	   behaviors	   the	   primary	  target	  of	  treatment.	  In	  some	  treatments	  the	  role	  of	  these	  factors	  in	  IBS	  have	  been	  acknowledged,	   but	   other	   sources	   of	   stress	   such	   as	   interpersonal	   relationships	  and	   maladaptive	   cognitions	   about	   the	   self	   and	   the	   world	   seem	   to	   have	   been	  given	   equal	   or	   more	   weight	   as	   maintaining	   factors.	   The	   common	   inclusion	   of	  relaxation	   techniques	   in	   cognitive	   behavioral	   therapies	   could	   indicate	   that	   the	  primary	   source	   of	   symptom-­‐inducing	   stress	   has	   not	   been	   identified	   in	   those	  treatments.	   If	   this	   primary	   source	   has	   been	   identified	   and	   is	   targeted	   by	  treatment,	   relaxation	   might	   not	   be	   necessary	   to	   control	   the	   stress	   emanating	  from	   this	   source.	   Perhaps	   the	   inconsistencies	   in	   effects	   between	   trials	   of	  cognitive	  behavioral	   therapies	   are	  an	   indication	   that	   they	  have	  partly	   failed	   to	  identify	  the	  primary	  source	  of	  symptom-­‐inducing	  stress.	  
1.6 OUTLINING	  A	  NEW	  TREATMENT	  APPROACH	  During	   recent	   years	   a	   new	   development	   within	   the	   cognitive	   behavioral	  tradition	   has	   gained	   interest.	   This	   “third	   wave”	   of	   cognitive	   and	   behavioral	  therapies	   is	   aimed	   at	   reducing	   emotional	   avoidance	   and	   increasing	   behavioral	  flexibility	   to	   promote	  mental	   and	   physical	   health.	   A	   new	   format	   of	   treatment-­‐delivery	  has	  also	  emerged	  during	  the	  last	  decade.	  Using	  the	  internet	  to	  provide	  evidence-­‐based	  treatments	  has	  shown	  efficacy	  in	  decreasing	  symptom	  levels	  in	  a	  number	  of	  disorders.	  Exposure	  is	  considered	  by	  some	  to	  be	  a	  key	  intervention	  in	  standard	  CBT	  but	  has	  not	  been	  an	  integral	  part	  of	  CBT-­‐treatments	  for	  IBS.	  Below,	  the	  principles	  of	  these	  new	  developments	  and	  how	  they,	  together	  with	  exposure,	  can	  be	  applied	  to	  IBS	  is	  discussed.	  	  
1.6.1 EXPERIENTIAL	  AVOIDANCE	  The	   process	   through	  which	   IBS	   symptoms	   become	   associated	  with	   stress	   and	  avoidance	  behaviors,	  leading	  to	  even	  more	  symptoms,	  bears	  much	  resemblance	  to	   the	   concept	   of	   experiential	   avoidance.	   According	   to	   Hayes	   et	   al.	   (149),	  experiential	  avoidance	  is	  an	  unwillingness	  to	  experience	  aversive	  private	  events	  such	   as	   bodily	   sensations,	   emotions,	   and	   thoughts.	   This	   unwillingness	   is	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manifested	  as	  behaviors	  that	  serve	  to	  control	  or	  escape	  both	  the	  events	  and	  the	  contexts	   that	   occasion	   them.	   This	   maps	   well	   onto	   IBS,	   where	   symptoms	   and	  several	   symptom-­‐related	   situations	   have	   become	   aversive.	   IBS	   patients	   try	   to	  alter	   their	   symptoms,	   using	   e.g.	   symptom-­‐controlling	   drugs,	   distraction,	   or	  relaxation,	   or	   to	   avoid	   situations	   that	   are	   likely	   to	   cause	   symptoms,	   e.g.	   eating	  certain	   foods	   or	   stressful	   situations.	   Furthermore,	   they	   avoid	   situations	   that	  would	  be	   threatening	   if	   symptoms	  were	  present,	  e.g.	   social	  events	  or	  being	   far	  from	  a	  restroom	  (101).	  Experiential	  avoidance	  is	  proposed	  to	  be	  a	  core	  component	  of	  psychopathology	  when	  it	   is	  used	  as	  a	  strategy	  to	  control	  private	  events	  that	  are	  not	  controllable	  by	  will,	  or	  when	  the	  process	  of	  avoidance	  increases	  the	  strength	  of	  the	  undesired	  experience,	   or	  when	   the	  means	  of	   avoidance	   create	   additional	   suffering	   (149).	  Again,	   IBS	   fits	  well	  with	   this	  process.	  The	  biological	  mechanisms	   that	  underlie	  IBS	  symptoms	  (e.g.	  motility	  and	  pain	  processing)	  cannot	  be	  controlled	  directly	  and	  as	  GI	  symptoms	  are	  part	  of	  normal	  gut	  functioning	  they	  cannot	  be	  avoided	  entirely.	  Nor	   is	   conditioned	   fear	  of	   IBS	  symptoms	  and	  related	  situations	  under	  willful	   control.	   The	   avoidance	   of	   IBS	   symptoms	  or	   symptom-­‐related	   situations	  has	   also	   been	   associated	   with	   increased	   symptom	   intensity	   and	   functional	  impairment	   (101)	   (i.e.	   the	   avoidance	   increases	   the	   strength	   of	   the	   undesired	  experience	  and	  additional	  suffering).	  	  The	  role	  of	  avoidance	  of	  negative	  emotions	  and	  thoughts	   is	  also	  emphasized	  in	  contemporary	   models	   of	   many	   of	   the	   psychological	   disorders	   that	   show	   high	  comorbidity	   with	   IBS,	   e.g.	   panic	   disorder	   (150),	   generalized	   anxiety	   disorder	  (151),	   and	   depression	   (152).	   In	   addition,	   IBS	   patients	   show	   increased	  prevalence	  of	  chronic	  pain	  (153),	  which	  is	  also	  heavily	  influenced	  by	  symptom-­‐related	   fear	   and	   avoidance	   behaviors	   (154).	   Rather	   than	   being	   separate	  disorders	   within	   one	   patient,	   IBS	   and	   these	   accompanying	   psychological	   and	  physical	   disorders	   could	   therefore	   be	   regarded	   as	   a	   behavioral	   pattern	   of	  experiential	  avoidance.	  Experiential	  avoidance	  is	  a	  key	  concept	  within	  the	  “third	  wave”	  of	  cognitive	  and	  behavioral	  therapies,	  which	  includes	  therapeutic	  approaches	  such	  as	  acceptance	  and	   commitment	   therapy	   (ACT),	   dialectic	   behavior	   therapy	   (DBT),	   and	  mindfulness-­‐based	   cognitive	   therapy	   (155).	   In	  ACT	  and	  DBT,	  principal	   aims	  of	  the	   treatment	   are	   to	   increase	   acceptance	   instead	   of	   avoidance	   of	   negative	  experiences,	   by	   promoting	   behavioral	   flexibility	   in	   the	   presence	   of	   aversive	  stimuli	   instead	   of	   exercising	   control	   over	   these	   stimuli	   (155,	   156).	   Integral	   in	  both	  treatments	  is	  the	  use	  of	  acceptance	  and	  mindfulness	  techniques	  to	  achieve	  these	  goals.	  
1.6.2 MINDFULNESS	  AND	  ACCEPTANCE	  Mindfulness	   is	  a	  practice	   that	  originates	   from	  Buddhist	   tradition	  and	  has	  been	  used	   within	   that	   tradition	   to	   decrease	   the	   mental	   suffering	   that	   is	   regarded	  ubiquitous	   in	   human	   existence	   (157).	   The	  mindfulness-­‐based	   stress	   reduction	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program,	   published	   in	   1982,	   introduced	  mindfulness	   as	   a	   clinical	   intervention	  for	  chronic	  pain	  (158).	  Since	   then	  mindfulness	  has	  been	  evaluated	  as	  a	  clinical	  intervention	  for	  a	  variety	  of	  disorders.	  In	  a	  recent	  meta-­‐analysis,	  Hofmann	  et	  al.	  included	   studies	   that	   used	  mindfulness	   as	   a	   stand-­‐alone	   treatment	   for	   anxiety	  disorders,	   depression,	   pain	   disorders,	   medical	   problems,	   attention	   deficit	  hyperactivity	   disorder,	   and	   eating	   disorders	   (159).	   Overall,	   mindfulness	   was	  moderately	   effective	   in	   improving	   anxiety	   and	   mood	   symptoms.	   However,	   in	  patients	   suffering	   from	   mood	   or	   anxiety	   disorders	   mindfulness	   interventions	  were	  associated	  with	  large	  improvements.	  	  Although	   mindfulness	   is	   gaining	   popularity	   there	   are	   many	   different	   clinical	  applications	   of	   mindfulness	   with	   significant	   differences	   in	   underlying	   theory,	  training,	   aim,	   and	   hypothesized	  mechanisms	   (160).	   Notably,	   in	   ACT	   and	   DBT,	  mindfulness	  is	  not	  a	  stand-­‐alone	  component	  but	  is	  used	  as	  a	  strategy	  within	  the	  overall	  agenda	  of	  increasing	  acceptance	  and	  behavioral	  flexibility	  (160).	  Within	  DBT,	   mindfulness	   is	   hypothesized	   to	   improve	   emotional	   regulation	   and	  attentional	   control	  while	   also	   functioning	   as	   exposure	   to	   aversive	   experiences	  and	   teaching	   new	   behavioral	   responses,	   i.e.	   acceptance	   instead	   of	   attempts	   to	  avoid	  or	  alter	  these	  experiences	  (156).	  In	  ACT,	  mindfulness	  and	  acceptance	  are	  closely	  linked	  concepts,	  focused	  on	  experiencing	  internal	  events	  without	  judging	  them	  or	  trying	  to	  alter	  them	  (160).	  Mindfulness	  has	  been	  suggested	  to	  consist	  of	  several	   behavioral	   dimensions.	  Observing	   is	   the	   process	   of	   observing	   internal	  and	   external	   experiences,	  describing	   refers	   to	   labeling	   of	   internal	   experiences,	  
acting	  with	  awareness	  is	  an	  ongoing	  attention	  to	  one’s	  activities,	  nonjudging	  and	  
nonreactivity	   of	   inner	   experiences	   are	   two	   processes	   that	   refer	   to	   taking	   a	  nonevaluative	   stance	   towards	   thoughts	   and	   feelings	   and	   not	   reacting	   to	   these	  experiences,	   i.e.	   letting	   them	   come	   and	   go	   without	   getting	   caught	   up	   in	   them	  (161).	  Thus,	   mindfulness	   is	   a	   behavior	   that	   is	   opposite	   to	   distraction	   from	   or	  suppression	  of	   aversive	   inner	   stimuli	   such	  as	   thoughts	  or	   emotions.	  This	   is	   an	  important	  aspect	  of	  mindfulness,	  as	  attempts	  to	  control	  thoughts	  and	  emotions	  often	  have	  the	  paradoxical	  effect	  of	  increasing	  the	  strength	  of	  the	  target	  thoughts	  or	  emotions	  (162).	  In	  laboratory	  studies,	  mindfulness	  through	  focused	  breathing	  has	   led	   to	   better	   improvement	   in	   dysphoric	   mood	   than	   rumination	   and	  distraction	   (163)	   and	   less	   reactivity	   to	   negative	   images	   than	   worry	   and	   free	  mind-­‐wandering	   (164).	   Encouraging	   acceptance	   instead	   of	   control	   of	   negative	  experiences	   has	   been	   shown	   to	   decrease	   the	   fear	   response	   and	   avoidance	  impulses	   after	   inhalation	   of	   carbon	   dioxide	   enriched	   air	   (inducing	   panic-­‐like	  symptoms),	  when	  compared	  to	  emotional	  suppression	  (165)	  and	  diaphragmatic	  breathing	   (166).	   Interestingly,	   outside	   mindfulness	   research	   the	   behavior	   of	  labeling	  or	  describing	  aversive	  stimuli	  has	  been	  found	  to	  modulate	  the	  response	  to	  these	  stimuli.	  Sensory	  monitoring,	   i.e.	  describing	  the	  physical	  characteristics	  of	  a	  sensation,	  has	  been	  shown	  to	  decrease	  the	  unpleasantness	  of	  painful	  stimuli	  (167).	  Matching	  an	  angry	  or	  scared	  face	  to	  a	  label	  describing	  the	  emotion	  leads	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to	   larger	   down-­‐regulation	   in	   amygdala	   activity,	   a	   brain	   region	   involved	   in	   the	  expression	  of	  fear	  (168),	  than	  matching	  with	  another	  angry/scared	  face	  (169)	  or	  the	  gender	  of	  the	  face	  (170).	  Furthermore,	  the	  effect	  of	  repeated	  exposure	  seems	  to	   be	   facilitated	   when	   aversive	   stimuli	   are	   paired	   with	   labels	   describing	   the	  stimuli	  (171).	  
1.6.3 EXPOSURE	  TREATMENT	  Exposure	   treatment	   is	   probably	   among	   the	   most	   powerful	   interventions	   to	  reduce	   fear	  or	  anxiety	  associated	  with	  a	   stimulus	   (172).	  The	  main	  principle	  of	  exposure,	   to	   repeatedly	  expose	  oneself	   to	  a	   feared	  stimulus	   in	  order	   to	   reduce	  the	  fear	  of	  that	  stimulus,	  became	  widely	  recognized	  after	  Wolpe	  had	  developed	  systematic	   desensitization	   to	   treat	   specific	   phobias	   (173).	   The	   desensitization	  procedure	   included	   presenting	   the	   phobic	   stimuli	   to	   the	   patient	   while	   the	  patient	   was	   in	   a	   relaxed	   state.	   It	   was	   theorized	   that	   the	   relaxed	   state	   would	  “countercondition”	   and	   ultimately	   eliminate	   the	   fear	   elicited	   by	   the	   stimulus	  (172).	   However,	   systematic	   desensitization	   had	   only	   limited	   value	   in	   treating	  clinical	   fears	   and	   the	   relaxed	   state	   did	   not	   prove	   to	   be	   necessary	   in	   exposure	  treatments	  (172,	  173).	  In	  more	  recent	  models	  of	  exposure,	  it	  is	  emphasized	  that	  exposure	   should	   target	   experiential	   avoidance	  by	   eliciting	   a	   fear	   response	  and	  facilitate	   acting	   in	   a	  manner	   that	   is	   not	   in	   accord	  with	   the	   fear	   response,	   e.g.	  approaching	   instead	   of	   avoiding	   (172,	   173).	   Within	   ACT,	   the	   purpose	   of	  exposure	  is	  not	  to	  reduce	  the	  fear	  response	  but	  to	  increase	  behavioral	  flexibility	  in	   the	   presence	   of	   stimuli	   that	   have	   previously	   narrowed	   the	   behavior	  repertoire,	  while	  being	  aware	  of	  and	  accepting	  the	  feelings	  elicited	  by	  the	  stimuli	  (155,	  174).	  Craske	   et	   al.	   recently	   summarized	   experimental	   studies	   of	   the	  mechanisms	   of	  exposure	   treatment	   (175).	   They	   concluded	   that	   effective	   exposure	   does	   not	  depend	   on	   fear	   reduction	   during	   exposure	   but	   rather	   on	   development	   of	   fear	  tolerance.	  Exposure	  exercises	  should	  be	  focused	  on	  violating	  the	  expectancies	  of	  the	   patient,	   both	   on	   automatic	   and	   propositional	   levels.	   That	   is,	   the	   exposure	  should	   provide	   new	   information	   both	   regarding	   what	   stimuli	   that	   follow	  previously	   conditioned	   stimuli	   and	   verbal	   predictions	   about	  what	  will	   happen	  during	   the	   exposure.	   Furthermore,	   the	   use	   of	   safety	   behaviors	   may	   interfere	  with	   the	   exposure	   since	   the	   expectancy	   violation	   might	   be	   attributed	   to	   the	  safety	   behavior	   and	   therefore	   not	   result	   in	   new	   learning.	   Finally,	   exposure	  exercises	  should	  be	  spaced	  over	  time	  and	  take	  place	  in	  varying	  context	  that	  have	  close	  resemblance	  to	  the	  real-­‐life	  contexts	  that	  evoke	  fear.	  
1.6.4 INTERNET-­‐DELIVERED	  COGNITIVE	  BEHAVIOR	  THERAPY	  In	  2009,	  Hunt	  et	  al.	  published	  the	  first	  study	  evaluating	  ICBT	  for	  IBS,	  consisting	  of	   relaxation	   training,	   cognitive	   restructuring,	   exposure	   exercises,	   and	  behavioral	   experiments	   (176).	   This	   study	   used	   e-­‐mail	   to	   provide	   therapist	  contact	   and	   the	   results	   were	   promising	   with	   large	   improvements	   in	   IBS	  
 	   19	  
symptoms	   compared	   to	   a	   waiting	   list.	   However,	   the	   study	   had	   large	   attrition	  rates	  and	  had	  not	  employed	  any	  diagnostic	  procedure.	  There	   are	   many	   different	   approaches	   that	   use	   the	   internet	   to	   deliver	  psychological	   treatments.	   The	   ICBT	   employed	   by	   Hunt	   et	   al.	   has	   many	  similarities	   to	   face-­‐to-­‐face	  CBT.	   In	   ICBT	   the	  patients	   learn	  about	   the	   treatment	  interventions	  by	   reading	   self-­‐help	   texts	   that	   contain	  both	   educational	  material	  and	  instructions	  on	  how	  to	  perform	  the	  exercises	  that	  constitute	  the	  treatment.	  The	  general	  principle	  is	  that	  the	  treatment	  should	  reflect	  face-­‐to-­‐face	  therapy	  in	  terms	  of	   content,	  but	   instead	  of	   including	   face-­‐to-­‐face	   time	  with	  a	   therapist	  an	  online	   therapist	   guides	   the	   patient	   through	   the	   course	   of	   the	   treatment.	   The	  therapist	   contact	   is	  most	   often	   asynchronous,	   i.e.	   the	   communication	  does	   not	  take	  place	  trough	  real-­‐time	  chats	  or	  video	  conferencing.	  Instead,	  the	  patient	  and	  therapist	   send	   messages	   to	   each	   other	   when	   it	   suits	   them,	   using	   e-­‐mail	   or	  websites	  with	   integrated	  messaging	  systems.	  Usually,	   there	   is	  agreement	  upon	  how	  often	  the	  patient	  should	  check	  in	  with	  the	  therapist,	  e.g.	  once	  a	  week,	  and	  how	   fast	   the	   patient	   should	   expect	   to	   get	   answers	   from	   their	   therapist,	   e.g.	  within	  24-­‐48	  hours	  during	  weekdays.	  	  The	  therapist	  gives	  feedback	  on	  homework	  exercises	  completed	  by	  the	  patient,	  answers	  questions,	  and	  provides	  general	  support	  in	  the	  patient’s	  work	  with	  the	  treatment.	  An	  important	  therapist	  task	  is	  to	  grant	  the	  patient	  gradual	  access	  to	  the	  treatment	  material.	  Often,	  the	  treatment	  material	  is	  not	  presented	  all	  at	  once	  but	   is	   divided	   into	   chapters,	   or	   modules,	   similar	   to	   how	   manualized	   CBT	   is	  scripted	  session-­‐by-­‐session.	  To	  get	  access	   to	   the	  next	  module,	  or	   “session”,	   the	  patient	  has	  to	  complete	  the	  homework	  of	  the	  current	  module	  and	  report	  it	  to	  the	  therapist.	   In	   ICBT,	   therapist	   time	   is	  dramatically	   reduced	  compared	   to	   face-­‐to-­‐face	   CBT.	   Therapists	   usually	   spend	   about	   10	   minutes	   per	   week	   and	   patient	  (177).	   However,	   the	   outcome	   in	   ICBT	   seems	   to	   be	   dependent	   on	   a	   certain	  amount	  of	  therapist	  contact.	  Studies	  including	  very	  little	  or	  no	  therapist	  contact	  have	   lower	   treatment	   effects	   than	   studies	   including	   regular	   contact	   with	   a	  therapist	  (178,	  179).	  ICBT	  carries	  many	  advantages	  compared	   to	   traditional	   face-­‐to-­‐face	  CBT.	  These	  include	  larger	  patient	  volumes	  per	  therapist,	  no	  need	  for	  patients	  to	  take	  time	  off	  work	   to	   travel	   to	   the	   therapist’s	   office,	   and	   patients	   living	   in	   rural	   and	   urban	  areas	  have	  equal	  access	  to	  treatment.	  ICBT	  also	  comes	  with	  disadvantages.	  The	  format	   makes	   it	   harder,	   but	   not	   impossible,	   to	   tailor	   the	   treatment	   after	  individual	   needs	   and	   idiosyncrasies	   in	   behavioral	   patterns.	   This	   makes	   it	  essential	   that	   the	   manuals	   are	   comprehensive	   and	   cover	   the	   majority	   of	  behavioral	   patterns	   that	   patients	   present	   with.	   The	   target	   disorder	   must	  therefore	   be	   well	   characterized	   and	   the	   diagnostic	   procedure	   must	   select	   the	  patients	  who	   fit	   the	  profile	   that	   is	   assumed	   in	   the	  manual.	   The	   treatment	   also	  demands	  much	  from	  the	  patients’	  ability	  to	  plan	  their	  treatment,	  to	  read	  the	  self-­‐
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help	  material	  and	  fit	  instructions	  and	  examples	  to	  their	  own	  behavioral	  patterns,	  and	  to	  use	  the	  internet	  to	  communicate	  with	  their	  therapist.	  During	  the	  last	  decade,	  several	  trials	  have	  evaluated	  ICBT	  for	  various	  psychiatric	  disorders	   and	   health	   problems.	   One	   of	   the	   first	   studies	   employing	   the	   ICBT	  model	  described	  here	  targeted	  chronic	  headache	  (180).	  Later	  studies	  within	  the	  behavioral	  medicine	  field	  have	  been	  conducted	  on	  e.g.	  tinnitus,	  chronic	  pain,	  and	  insomnia	   with	   effect	   sizes	   similar	   to	   face-­‐to-­‐face	   treatment	   (181).	   Within	   the	  field	  of	  psychiatric	  disorders,	   ICBT	  has	  shown	  effectiveness	   for	  panic	  disorder,	  social	   phobia,	   post-­‐traumatic	   stress	   disorder,	   depression,	   and	   bulimia	  nervosa/binge	   eating	   disorder	   (182).	   Recent	   studies	   from	   our	   research	   group	  have	   indicated	   that	   ICBT	   is	   effective	   for	  hypochondriasis	   (183)	   and	  may	  be	   as	  effective	   as	   cognitive	   behavioral	   group	   therapy	   in	   the	   treatment	   of	   panic	  disorder	  (184)	  and	  social	  anxiety	  disorder	  (185).	  
1.6.5 SYNTHESIS	  IBS	  is	  a	  prevalent,	  costly,	  and	  debilitating	  disorder.	  Many	  patients	  with	  IBS	  also	  present	   with	   psychiatric	   and	   psychological	   problems.	   Pharmacological	  treatments	   come	  with	   side	   effects	   and	   require	   continuous	   use	   to	   be	   effective.	  Stress	  has	  been	  implicated	  as	  a	  cause	  of	  the	  major	  symptoms	  in	  IBS.	  Symptom-­‐related	  fear	  and	  avoidance	  behaviors	  seem	  to	  be	  the	  most	  distinguishing	  factors	  in	   IBS	   and	   are	   related	   to	   illness	   severity.	   Although	   several	   psychological	  treatment	   approaches	   exist,	   none	   of	   them	   have	   symptom-­‐related	   fear	   and	  avoidance	   behaviors	   as	   their	   primary	   target.	   Psychological	   treatments	   are	   not	  accessible	  for	  the	  majority	  of	  IBS	  patients.	  There	  is	  an	  obvious	  application	  for	  exposure	  in	  the	  treatment	  of	  IBS.	  By	  exposing	  themselves	   to	   IBS	   symptoms	   and	   avoided	   situations,	   IBS	   patients	   should	  experience	   reductions	   in	   fear	   of	   IBS	   symptoms.	  However,	   these	   patients	   often	  show	  a	  wide	  repertoire	  of	  avoidance	  behaviors,	  as	  mirrored	  by	   the	  psychiatric	  and	  psychological	  comorbidities	  they	  present	  with.	  Within	  the	  third	  wave	  of	  CBT	  there	   is	   an	   emphasis	   on	   acceptance	   of	   inescapable	   negative	   experiences	   and	  behavioral	  flexibility	   in	  the	  presence	  of	  these	  experiences.	  Presenting	  exposure	  exercises	   in	   a	   context	   of	   acceptance	   and	   behavioral	   flexibility	   and	   using	  mindfulness	   to	   potentiate	   the	   exposure	  may	   both	   be	   specifically	   targeting	   IBS	  and	   broadly	   targeting	   an	   avoidant	   behavioral	   pattern.	   Using	   the	   internet	   to	  provide	   the	   treatment	   allows	   for	   large-­‐scale	   implementations,	   which	   is	  necessary	  given	  the	  large	  prevalence	  of	  IBS.	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2. AIMS	  OF	  THE	  THESIS	  The	   overarching	   aim	   of	   this	   thesis	   was	   to	   develop	   and	   evaluate	   an	   effective	  psychological	  treatment	  for	  IBS	  that	  can	  be	  made	  accessible	  to	  a	  large	  number	  of	  IBS	  patients.	  The	  means	  to	  achieve	  this	  aim	  were	  to	  develop	  an	  exposure-­‐based	  CBT	   treatment	   that	   emphasized	   acceptance	   and	   behavioral	   flexibility	   in	  response	  to	  IBS-­‐related	  experiences	  and	  deliver	  this	  treatment	  via	  the	  internet.	  	  Five	   studies	   were	   conducted	   to	   evaluate	   the	   effectiveness	   of	   these	   means	   in	  achieving	  the	  aim.	  
2.1 STUDY	  I	  The	   aim	   of	   this	   study	   was	   to	   evaluate	   exposure-­‐based	   group	   CBT	   in	   the	  treatment	   of	   IBS.	   Participants	   were	   recruited	   through	   referral	   from	  gastroenterological	  clinics.	  We	  hypothesized	  that	  engaging	  in	  exposure	  exercises	  aided	   by	   mindful	   awareness	   would	   improve	   IBS-­‐symptoms,	   quality	   of	   life,	   GI	  symptom-­‐specific	  anxiety,	  and	  global	  functioning.	  We	  also	  hypothesized	  that	  the	  treatment	   would	   increase	   the	   willingness	   to	   be	   in	   contact	   with	   negative	  experiences.	   This	   would	   lead	   to	   a	   general	   improvement	   in	   mental	   health	   as	  expressed	   by	   psychiatric	   diagnoses.	   We	   also	   hypothesized	   that	   these	  improvements	  would	  be	  maintained	  6	  months	  after	  treatment.	  
2.2 STUDY	  II	  The	  aim	  of	  this	  study	  was	  to	  evaluate	  exposure-­‐based	  ICBT	  in	  the	  treatment	  of	  IBS.	   Participants	   were	   recruited	   through	   self-­‐referral.	   We	   hypothesized	   that,	  compared	   to	   a	  waiting	   list	   control	   group,	   the	   treatment	   group	  would	   improve	  IBS-­‐symptoms,	   quality	   of	   life,	   GI	   symptom-­‐specific	   anxiety,	   depressive	  symptoms,	   and	   global	   functioning.	   We	   also	   hypothesized	   that	   these	  improvements	  would	  be	  maintained	  3	  months	  after	  treatment.	  
2.3 STUDY	  III	  The	   aim	  of	   this	   study	  was	   to	   evaluate	   the	   long-­‐term	  effects	   of	   exposure-­‐based	  ICBT	   for	   IBS.	   The	   participants	   from	   study	   II	   were	   included	   in	   this	   study.	   We	  hypothesized	   that	   improvements	   in	   IBS	   symptoms,	   quality	   of	   life,	   and	   GI	  symptom-­‐specific	   anxiety	   that	   had	   been	   achieved	   in	   treatment	   would	   be	  maintained	  15-­‐18	  months	  after	  treatment.	  
2.4 STUDY	  IV	  The	  aim	  of	   this	  study	  was	   to	   investigate	   the	  effectiveness	  and	  clinical	  utility	  of	  exposure-­‐based	   ICBT	   within	   regular	   clinical	   practice.	   Participants	   were	  consecutively	  recruited	  from	  a	  gastroenterological	  clinic.	  We	  hypothesized	  that,	  compared	   to	   a	  waiting	   list	   control	   group,	   the	   treatment	   group	  would	   improve	  IBS-­‐symptoms,	   quality	   of	   life,	   GI	   symptom-­‐specific	   anxiety,	   depressive	  symptoms,	   and	   global	   functioning.	   We	   also	   hypothesized	   that	   these	  improvements	  would	  be	  maintained	  12	  months	  after	  treatment.	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2.5 STUDY	  V	  The	  aim	  of	  this	  study	  was	  to	   investigate	  the	  specificity	  of	  exposure-­‐based	  ICBT	  for	   IBS.	   We	   therefore	   compared	   it	   with	   a	   credible	   internet-­‐delivered	   control	  treatment	   based	   on	   stress	   management	   principles.	   Participants	   were	   self-­‐referred.	  We	   hypothesized	   that	   the	   treatments	  would	   be	   perceived	   as	   equally	  credible	  by	  the	  participants	  but	  that	  exposure-­‐based	  ICBT	  would	  be	  superior	  to	  internet-­‐delivered	   stress	   management	   in	   reducing	   IBS-­‐symptoms.	   We	   also	  hypothesized	  that	  this	  difference	  would	  be	  maintained	  6	  months	  after	  treatment.	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3. THE	  EMPIRICAL	  STUDIES	  First	   the	   common	   elements	   of	   the	   studies	   are	   presented.	   Then	   each	   study	   is	  presented	  with	  details	  on	  participant	  recruitment,	  design,	  analysis,	  results,	  and	  methodological	  discussions.	  Finally,	  the	  results	  on	  IBS-­‐specific	  outcomes	  shared	  between	   the	   studies	   are	   summarized.	   Table	   1	   provides	   an	   overview	   of	   the	  studies’	   characteristics	   with	   regards	   to	   aims,	   design,	   assessment	   points,	   and	  participant	  demographics.	  
3.1 MEASURES	  Table	  2	  provides	  an	  overview	  of	  the	  outcome	  measures	  used	  in	  each	  study.	  In	  studies	  II-­‐V	  all	  self-­‐assessments	  except	  the	  GI	  symptom	  diary	  were	  administered	  online.	  Online	  assessment	  has	  been	  shown	  to	  be	  reliable	  and	  produces	  results	  very	  similar	  to	  traditional	  paper-­‐and-­‐pencil	  administration	  (186).	  	  
3.1.1 MEASURES	  OF	  IBS	  SYMPTOMS	  In	   studies	   I	   and	   II	   the	   GI	   symptom	   diary	   (187)	   was	   used.	   It	   is	   a	   measure	   of	  primary	  IBS	  symptoms	  (abdominal	  pain	  and	  tenderness,	  diarrhea,	  constipation,	  and	   bloating)	   and	   additional	   common	   GI	   symptoms	   (flatulence,	   belching	   and	  nausea).	   Based	   on	   the	   primary	   symptoms,	   a	   relative	   change	   score	   between	   -­‐1	  and	  1	  can	  be	  calculated	  (CPSR;	  125).	  A	  CPSR	  score	  of	  ≥	  0.5,	  which	  means	  at	  least	  50	  %	   reduction	   in	   primary	   symptoms,	   is	   considered	   a	   clinically	   significant	  improvement	  (188).	  Studies	  II-­‐V	  used	  the	  gastrointestinal	  symptom	  rating	  scale	  –	   IBS	   version	   (GSRS-­‐IBS;	   189),	   which	   measures	   the	   severity	   of	   GI	   symptoms	  experienced	   in	   the	   last	   week.	   Since	   IBS-­‐symptoms	   have	   been	   shown	   to	   be	  intermittently	   clustered	   and	   occurring	   about	   once	   a	  week	   (190),	   three	   to	   four	  weeks	   of	   symptom	  monitoring	   with	   the	   GI	   symptom	   diary	   and	   GSRS-­‐IBS	   was	  used	  to	  establish	  a	  reliable	  assessment	  of	  symptom	  severity	  in	  all	  studies.	  	  In	   studies	   III	   and	   V	   we	   used	   another	   measure	   of	   clinically	   significant	  improvement.	   Adequate	   relief	   of	   IBS	   symptoms	   was	   assessed	   by	   asking	   the	  participants:	   “In	   the	  past	  week,	  have	  you	  had	  adequate	   relief	   from	   IBS	  pain	  or	  discomfort?”(191).	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Table	  2.	  Outcome	  measures	  used	  in	  the	  studies.	  
Measure	   Study	  I	   Study	  II	   Study	  III	   Study	  IV	   Study	  V	  
GI	  symptom	  diary	   Pre	  
Post	  
6	  mo	  f-­‐u	  
Pre	  
Post	  
	   	   	  
GSRS-­‐IBS	   	   Pre	  
Post	  
3	  mo	  f-­‐u	  
15-­‐18	  mo	  f-­‐u	   Pre	  
Post	  
12	  mo	  f-­‐u	  
Pre	  
Post	  
6	  mo	  f-­‐u	  
Adequate	  relief	   	   	   15-­‐18	  mo	  f-­‐u	   	   Post	  
6	  mo	  f-­‐u	  
IBS-­‐QOL	   Pre	  
Post	  
6	  mo	  f-­‐u	  
Pre	  
Post	  
3	  mo	  f-­‐u	  
15-­‐18	  mo	  f-­‐u	   Pre	  
Post	  
12	  mo	  f-­‐u	  
Pre	  
Post	  
6	  mo	  f-­‐u	  
VSI	   Pre	  
Post	  
6	  mo	  f-­‐u	  
Pre	  
Post	  
3	  mo	  f-­‐u	  
15-­‐18	  mo	  f-­‐u	   Pre	  
Post	  
12	  mo	  f-­‐u	  
Pre	  
Post	  
6	  mo	  f-­‐u	  
CSFBD	   	   	   	   	   Pre	  
Post	  
6	  mo	  f-­‐u	  
MADRS-­‐S	   Pre	  
Post	  




	   Pre	  
Post	  
12	  mo	  f-­‐u	  
	  
Sheehan	  disability	  scales	   Pre	  
Post	  




	   Pre	  
Post	  
12	  mo	  f-­‐u	  
	  
HADS	   	   	   	   	   Pre	  
Post	  
6	  mo	  f-­‐u	  
PSS	   	   	   	   	   Pre	  
Post	  
6	  mo	  f-­‐u	  
MINI	  &	  CGI	   Pre	  
Post	  
6	  mo	  f-­‐u	  
	   	   	   	  
Treatment	  credibility	  scale	   	   During	  
treatment	  
	   	   During	  
treatment	  
Working	  alliance	  inventory	   	   	   	   	   During	  
treatment	  
For	  each	  study	  and	  outcome	  measure	  the	  assessment	  points	  are	  given.	  Pre:	  pre-­‐treatment	  
assessment;	  Post:	  post-­‐treatment	  assessment,	  X	  mo	  f-­‐u:	  Follow-­‐up	  assessment	  X	  months	  after	  
treatment.	  	  
3.1.3 MEASURES	  OF	  GENERAL	  DISTRESS	  The	  Montgomery	  Åsberg	  depression	  rating	  scale	  –	  self	  report	  (MADRS-­‐S;	  194)	  is	  a	  measure	  of	  depressive	  symptoms.	  The	  Sheehan	  disability	  scales	   (195)	  assess	  symptom-­‐induced	   disability	   in	   three	   domains,	   social,	   work,	   and	   family.	   The	  MADRS-­‐S	  and	  Sheehan	  disability	  scales	  were	  used	  in	  studies	  I,	  II,	  and	  IV.	  	  In	  Study	  V	  the	  10-­‐item	  version	  of	  the	  perceived	  stress	  scale	  (PSS;	  196)	  was	  used	  to	  measure	  the	  degree	  to	  which	  daily	  situations	  were	  perceived	  as	  stressful	  by	  the	  participants.	  In	  the	  same	  study	  we	  used	  the	  hospital	  anxiety	  and	  depression	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scale	  (HADS;	  197),	  which	  measures	  the	  levels	  of	  anxiety	  and	  depression	  on	  two	  separate	  subscales.	  In	  study	  I	  psychiatric	   interviews	  were	  conducted	  by	  the	  study	  psychiatrist	  and	  included	  the	  mini-­‐international	  neuropsychiatric	  interview	  (MINI;	  198)	  and	  the	  clinical	  global	  impression	  scale	  (CGI;	  199).	  	  
3.1.4 MEASURES	  OF	  TREATMENT	  PROCESS	  VARIABLES	  In	  studies	  II	  and	  V	  we	  used	  the	  treatment	  credibility	  scale	  (200)	  to	  measure	  how	  participants	   perceived	   the	   treatments,	   namely	   how	   credible	   the	   treatment	  seemed	  and	  how	  successful	  participants	  predicted	  that	  the	  treatment	  would	  be	  in	  alleviating	   their	  problems.	   In	   study	  V	  we	  also	   included	   the	  working	  alliance	  inventory	   (201)	   to	  measure	   how	   participants	   rated	   the	   quality	   of	   the	   contact	  with	  their	  online	  therapist.	  
3.2 EXPOSURE-­‐BASED	  COGNITIVE	  BEHAVIOR	  THERAPY	  Some	   adjustments	   in	   how	   the	   treatment	   was	   presented	   were	   made	   between	  each	  study	  based	  on	  how	  it	  was	  received	  by	  the	  participants.	  However,	  the	  main	  interventions	   and	   theoretical	   framing	   of	   the	   treatment	   were	   the	   same	  throughout	  all	   the	   studies.	  Below,	   the	   treatment	   is	  described	  more	  extensively	  than	  in	  the	  papers	  describing	  the	  studies.	  Two	   features	   of	   this	   treatment	   separate	   it	   from	   other	   CBT	   protocols	   for	   IBS.	  First,	   it	   is	   rooted	   in	   a	   behavioral	   and	   functional	   perspective	   in	   that	   it	   views	  human	  behavior	  as	   an	  adaptation	   to	  environmental	   contingencies	   (172).	  Thus,	  the	  behavioral,	  cognitive,	  and	  emotional	  dimensions	  of	  experiential	  avoidance	  in	  IBS	   are	   seen	   as	   learned	   responses	   to	   IBS-­‐related	   stimuli.	   Although	   they	   are	  maintaining	  factors	  in	  IBS	  they	  are	  themselves	  not	  caused	  by	  negative	  thinking	  patterns	   or	   some	   other	   behavioral	   predisposition.	   Instead,	   they	   are	   caused	   by	  historical	   associations	   between	   IBS	   symptoms	   and	   negative	   experiences	   and	  historical	   reinforcement	   of	   behaviors	   that	   have	   served	   to	   avoid	   and	   control	  these	   experiences.	   These	   reinforcers	   have	   typically	   been	   temporary	   relief	   of	  symptoms	   or	   anxiety.	   Second,	   this	   behavioral	   pattern	   is	   countered	   through	  acceptance	   of	   IBS	   symptoms	   and	   related	   cognitions	   and	   feelings	   through	  exposure	   exercises	   combined	   with	   mindful	   awareness.	   Mindful	   exposure	  changes	   the	   association	   between	   symptom-­‐related	   stimuli	   and	   fear	   but	   also	  introduces	   new	   consequences	   that	   can	   influence	   future	   behavior.	   These	  consequences	  are	   typically	   reinforcers	   that	  have	  come	   to	  occur	   less	   frequently	  or	   not	   at	   all	   because	   of	   the	   avoidant	   behavioral	   pattern.	   These	   may	   be	  reinforcers	   that	   are	   dependent	   on	   engaging	   in	   e.g.	   social	   events,	   spontaneous	  behavior,	  physical	  activity,	  or	  difficult	  tasks	  at	  work.	  The	  exposure-­‐based	  treatment	  consists	  of	  three	  main	  themes.	  The	  first	  theme	  is	  education	   about	   a	   psychological	   model	   of	   IBS,	   explaining	   the	   relationship	  between	   behaviors	   that	   serve	   to	   control	   or	   avoid	   symptoms,	   stress,	   symptom	  awareness,	   and	   symptom	   severity.	   The	   patients’	   own	   experiences	   of	   the	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historical	   short-­‐term	   reinforcement	   of	   avoidance	   and	   control	   behaviors	   and	  ongoing	   detrimental	   effects	   of	   these	   behaviors	   on	   quality	   of	   life	   are	   discussed	  from	  this	  perspective.	  The	   second	   theme	   is	   mindfulness	   and	   acceptance;	   patients	   are	   taught	   a	   15	  minute	  mindfulness	  exercise	  to	  be	  practiced	  daily	  and	  a	  brief	  exercise	  aimed	  at	  bringing	   the	   patient	   into	   immediate	   awareness	   of	   current	   GI	   symptoms,	  thoughts,	  feelings,	  and	  behavioral	  impulses.	  Negative	  thoughts	  in	  the	  presence	  of	  aversive	   stimuli	   are	   explained	   to	   be	   a	   natural	   consequence	   of	   the	   negative	  valence	  of	  these	  stimuli	  and	  are	  part	  of	  the	  avoidant	  behavioral	  pattern.	  Patients	  are	   encouraged	   to	   take	   an	   accepting	   stance	   towards	   these	   thoughts	   instead	   of	  trying	  to	  alter	  or	  suppress	  them.	  Changing	  the	  avoidant	  behavior	  will	  eventually	  attenuate	  dominating	  and	  disturbing	  negative	  thinking.	  The	  third	   theme	   is	  exposure,	  chiefly	  divided	   into	   three	  categories.	  1)	  Exercises	  that	   provoke	   symptoms,	   such	   as	   certain	   foods,	   physical	   activity,	   and	   stressful	  situations.	  2)	  Abolishment	  of	  behaviors	  that	  serve	  to	  control	  symptoms,	  such	  as	  distraction,	  excessive	  toilet	  visits,	  eating	  certain	  foods,	  resting,	  and	  taking	  over-­‐the-­‐counter	  medications.	  3)	  Exposure	  to	  real	  life	  contexts	  where	  symptoms	  are	  unwanted,	   such	   as	   attending	   a	   meeting	   when	   experiencing	   abdominal	   pain,	  riding	   the	   bus	   with	   fear	   of	   losing	   control	   of	   the	   bowels,	   or	   attending	   a	   party	  while	   feeling	   bloated	   and	   unattractive.	   These	   three	   categories	   of	   exposure	  exercises	   are	   often	   combined,	   e.g.	   eating	   symptom-­‐provoking	   food	   before	   a	  meeting	  while	  wearing	   uncomfortably	   tight	   clothes,	   and	   not	   visiting	   the	   toilet	  before	   the	  meeting.	   The	  problem	  with	   safety	   behaviors,	   i.e.	   behaviors	   that	   are	  believed	   to	   lower	   the	   risks	   associated	  with	   an	   exposure	   exercise,	   is	   explained	  and	  they	  are	  weaned.	  The	   exposure	   exercises	   are	   presented	   to	   serve	   two	   purposes.	   Engaging	   in	  exposure	   exercises	   will	   probably	   result	   in	   long-­‐term	   extinction	   of	   the	   fear	  response	  to	  the	  aversive	  stimuli,	  leading	  to	  reduction	  in	  symptoms.	  But	  exposure	  also	   serves	   to	   broaden	   the	   behavior	   repertoire	   in	   the	   presence	   of	   aversive	  stimuli.	  Using	  exposure	  exercises	  with	  the	  sole	  purpose	  to	  reduce	  IBS	  symptoms	  could	  prove	   to	  be	   insufficient.	   IBS	  symptoms	  are	  not	  under	  willful	   control	  and	  are	   part	   of	   the	   normal	   variations	   in	   gut	   functioning	   –	   thus	   even	   successfully	  treated	  patients	  will	  experience	  GI	  symptoms	  (but	  probably	  identify	  them	  as	  IBS	  symptoms)	   during	   the	   rest	   of	   their	   life.	   Fear-­‐responses	   to	   symptoms	   and	  associated	   situations	  may	   also	   linger	   even	   after	   successful	   exposure	   exercises.	  Thus,	   future	   variations	   in	   symptoms	  may	   trigger	   the	   fear	   response,	   leading	   to	  more	  symptoms	  and	  associated	  negative	  thoughts	  and	  emotions.	  This	  underlines	  the	   importance	   of	   using	   exposure	   exercises	   to	   practice	   reacting	   to	   aversive	  stimuli	  with	   behaviors	   that	   allow	   access	   to	   important	   reinforcers,	   rather	   than	  with	   avoidance	   or	   control	   behaviors	   that	   preclude	   the	   access	   to	   these	  reinforcers.	  This	  practice	  ensures	  that	  these	  reinforcers	  will	  be	  accessible	  even	  in	  future	  presence	  of	  these	  aversive	  experiences.	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Patients	   are	   also	   instructed	   on	   how	   to	   use	   mindfulness	   during	   exposure.	   By	  observing	   and	   labeling	   their	   environment,	   i.e.,	   aversive,	   neutral,	   and	   positive	  internal	  and	  external	  stimuli,	  they	  will	  counter	  distraction	  from	  and	  suppression	  of	  thoughts	  and	  emotions.	  By	  attending	  to	  any	  impulses	  to	  flee	  the	  situation	  or	  decrease	  the	  intensity	  of	  symptoms	  they	  will	  also	  be	  less	  inclined	  to	  act	  on	  these	  impulses.	   Patients	   are	   also	   instructed	   to	   predict	   how	   they	   think	   the	   exposure	  will	  play	  out	  before	  the	  exposure	  exercises.	  After	  completing	  the	  exercises	  they	  compare	  their	  experience	  with	  their	  prediction.	  Throughout	   treatment,	   acceptance	   of	   aversive	   experiences	   that	   cannot	   be	  controlled	  without	  causing	  secondary	  suffering	  is	  emphasized.	  Exposure	  to	  these	  experiences	   is	   conceptualized	   as	   acceptance	   of	   them	   and	   willingness	   to	   be	   in	  contact	  with	  them.	  At	  the	  end	  of	  treatment	  the	  risk	  of	  relapse	  into	  strategies	  of	  symptom	  control	  and	  avoidance	  is	  discussed.	  
3.3 INTERNET-­‐DELIVERED	  CBT	  Studies	  I,	  II,	  IV,	  and	  V	  employed	  ICBT	  as	  it	  is	  presented	  in	  the	  Background.	  The	  treatment	   was	   based	   on	   the	   exposure-­‐based	   CBT	   protocol.	   The	   treatment	  material	  was	  presented	  on	  printer-­‐friendly	  web	  pages	  and	  divided	  into	  several	  successive	  steps.	  All	  participants	  had	  an	  assigned	  online	  therapist.	  To	  progress	  through	   treatment,	  participants	  had	   to	   report	   that	   they	  had	  worked	   through	  a	  treatment	  step	  to	  get	  access	  to	  the	  next.	  During	  treatment,	  participants	  also	  had	  access	   to	   an	   online	   closed	   discussion	   forum	   where	   they	   could	   discuss	   their	  treatment	  with	  each	  other.	  
3.4 STUDY	  I	  Table	   3	   displays	   relevant	   effect	   sizes	   and	   proportions	   of	   clinically	   significant	  improvements	   together	   with	   results	   from	   associated	   statistical	   tests	   in	   all	  studies.	  All	  studies	  were	  approved	  by	  the	  regional	  ethics	  committee.	  
3.4.1 PARTICIPANTS	  Female	  participants,	  between	  the	  age	  of	  18	  and	  65,	  were	  included	  in	  the	  study	  if	  they	   had	   been	   diagnosed	   with	   IBS	   at	   a	   gastroenterological	   outpatient	   clinic.	  Patients	   were	   excluded	   if	   any	   somatic	   or	   psychiatric	   disorder	   deemed	   to	  interfere	  with	  treatment	  was	  present.	  Information	  about	  the	  study	  was	  spread	  to	  gastroenterological	  clinics	  in	  Stockholm,	  Sweden,	  and	  patients	  were	  referred	  to	  the	  study	  psychiatrist.	  Most	  participants	  were	   referred	   to	   the	  study	   from	  their	  gastroenterologist.	  A	  total	  of	  34	  participants	  were	  included.	  
3.4.2 INTERVENTION	  The	  group	  treatment	  consisted	  of	  10	  weekly	  2-­‐hour	  group	  sessions	  lead	  by	  two	  psychologists,	  with	  4-­‐6	  participants	   in	  each	  group.	  The	  first	   four	  sessions	  were	  focused	   on	   teaching	   the	   participants	   the	   psychological	   model	   underlying	   the	  treatment	  and	  mindfulness	  exercises.	  In	  the	  remaining	  six	  sessions	  the	  focus	  was	  on	   planning	   and	   evaluating	   between-­‐sessions	   exposure	   exercises.	   Throughout	  the	   treatment	   all	   sessions	   were	   therapist-­‐lead.	   Although	   participants	   in	   the	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group	   interacted	   during	   sessions	   and	   coffee	   breaks,	   sharing	   of	   personal	  information	  or	  peer-­‐support	  was	  not	  considered	  part	  of	  the	  therapeutic	  process	  and	  was	  not	  encouraged	  (nor	  discouraged)	  by	  the	  therapists.	  
3.4.3 ASSESSMENTS	  The	   study	   included	   a	   psychiatric	   assessment	   including	   the	  MINI	   and	   CGI.	   The	  self-­‐assessments	   included	   the	   GI	   symptom	   diary,	   IBS-­‐QOL,	   VSI,	   MADRS-­‐S,	   and	  Sheehan	   disability	   scales.	   All	   assessments	   were	   conducted	   at	   pre-­‐treatment,	  post-­‐treatment,	  and	  at	  6-­‐month	  follow-­‐up.	  
	  
Table	  3.	  Reported	  within-­‐	  and	  between-­‐groups	  effect	  sizes	  and	  proportion	  of	  
clinically	  significant	  improvements	  for	  all	  studies,	  together	  with	  results	  from	  
associated	  significance	  tests.	  
	   Study	  I	   	   Study	  II	   	   Study	  III	   	   Study	  IV	   	   Study	  V	  
Measure	   	   	   	   	   ICBT	   WL	   	   	   	   Post	   F-­‐U	  
The	  GI	  	  
symptom	  diary	  
	   	   	   	   	   	   	   	   	   	   	  
	  	  Primary	  symptoms	   0.83*	   	   0.83*	   	   	   	   	   	   	   	   	  
	  	  Pain	   0.64*	   	   0.64*	   	   	   	   	   	   	   	   	  
	  	  Constipation	   0.35*	   	   0.76	   	   	   	   	   	   	   	   	  
	  	  Diarrhea	   0.43	   	   0.32*	   	   	   	   	   	   	   	   	  
	  	  Bloating	   1.02*	   	   0.94*	   	   	   	   	   	   	   	   	  
%	  CPSR	  ≥	  0.5	  or	  	  
%	  Adequate	  relief	  
50%	   	   ICBT:	  40%	  
WL:	  2%*	  




GSRS-­‐IBS	   	   	   1.21*	   	   1.11*	   0.94*	   	   0.75*	   	   0.38*	   0.44*	  
IBS-­‐QOL	   1.30*	   	   0.93*	   	   0.91*	   0.94*	   	   0.82*	   	   0.51*	   0.31*	  
VSI	   1.40*	   	   0.64*	   	   0.79*	   0.79*	   	   0.74*	   	   0.33*	   0.37*	  
CSFBD	   	   	   	   	   	   	   	   	   	   0.52*	   0.36*	  
MADRS-­‐S	   0.59	   	   0.43*	   	   	   	   	   0.61	   	   	   	  
Sheehan	  disability	  
scales	  
1.21*	   	   0.47*	   	   	   	   	   0.21*	   	   	   	  
HADS	  anxiety	   	   	   	   	   	   	   	   	   	   0.04	   0.14	  
HADS	  depression	   	   	   	   	   	   	   	   	   	   0.01	   0.08	  
PSS	   	   	   	   	   	   	   	   	   	   -­‐0.02	   0.06	  
All	  effect	  sizes	  are	  Cohen’s	  d	  and	  *	  marks	  p<.05	  for	  associated	  statistical	  tests.	  
Study	  I:	  Within-­‐group	  effect	  sizes	  for	  improvements	  from	  pre-­‐treatment	  to	  post-­‐treatment	  	  
assessment.	  *Significant	  dependent	  t-­‐test.	  Study	  II:	  Between-­‐groups	  effect	  sizes	  comparing	  
treatment	  group	  and	  waiting	  list	  at	  post-­‐treatment.	  *Significant	  interaction	  effects	  of	  2x2	  repeated	  
measures	  ANOVA	  or	  Chi-­‐2	  for	  difference	  in	  CPSR	  proportions.	  Study	  III:	  Within-­‐group	  effect	  sizes	  for	  
improvements	  from	  pre-­‐treatment	  to	  15-­‐18-­‐month	  follow-­‐up	  with	  missing	  values	  replaced	  by	  pre-­‐
treatment	  scores	  based	  on	  all	  participants	  in	  study	  II	  and	  separately	  reported	  for	  Study	  II’s	  original	  
treatment	  group	  (ICBT)	  and	  waiting	  list	  after	  being	  crossed	  over	  to	  treatment	  (WL).	  *Significant	  
dependent	  t-­‐test.	  Study	  IV:	  Between-­‐groups	  effect	  sizes	  comparing	  treatment	  group	  and	  waiting	  list	  
at	  post-­‐treatment.	  *Significant	  interaction	  effects	  of	  mixed	  models	  analysis.	  Study	  V:	  Between-­‐
groups	  effect	  sizes	  comparing	  treatment	  group	  and	  waiting	  list	  at	  post-­‐treatment	  (Post)	  and	  6-­‐month	  
follow-­‐up	  (F-­‐U).	  *Significant	  interaction	  effects	  of	  mixed	  models	  analysis	  or	  Chi-­‐2	  for	  difference	  in	  
adequate	  relief	  proportions.	  	  
ICBT:	  Internet-­‐delivered	  exposure	  based	  CBT.	  ISM:	  Internet-­‐delivered	  stress	  management.	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3.4.4 ANALYSIS	  Dependent	  t-­‐tests	  were	  used	  to	  examine	  the	  treatment	  group’s	  change	  from	  pre-­‐treatment	   to	   post-­‐treatment	   and	   to	   test	   if	   treatment	   gains	   were	   sustained	   at	  follow-­‐up.	  At	  post-­‐treatment	  and	  follow-­‐up,	   the	  proportion	  of	  participants	  who	  had	   a	   CPSR	   score	   ≥	   0.5	   (50%	   improvement	   on	   primary	   GI	   symptoms),	   the	  proportion	  of	  participants	  who	  were	  recovered	  from	  diagnosable	  pre-­‐treatment	  psychiatric	   conditions,	   and	   the	   proportion	   of	   participants	   who	   were	   much	   or	  very	  much	  improved	  according	  to	  the	  CGI	  were	  calculated.	  
3.4.5 RESULTS	  Twenty-­‐nine	   of	   the	   34	   participants	   (85%)	   completed	   the	   post-­‐treatment	  assessment	  and	  30	  (88%)	  completed	  the	  6-­‐month	  follow-­‐up.	  Participants	  showed	  significant	  improvement	  on	  all	  symptoms	  measured	  by	  the	  GI	  symptom	  diary	  at	  post-­‐treatment,	  except	  for	  diarrhea.	  The	  treatment	  effects	  on	  bloating	  and	   the	  composite	  primary	  symptom	  score	  were	   large.	  The	  effects	  on	   the	   VSI,	   IBS-­‐QOL,	   and	   Sheehan	   disability	   scales	   were	   large	   and	   significant.	  Effects	  on	  MADRS-­‐S	  were	  non-­‐significant.	  All	  improvements	  were	  maintained	  at	  the	  6-­‐month	  follow-­‐up.	  The	  proportion	  of	  patients	  with	  CPSR	   scores	  ≥	  0.5	  was	  50%	  at	  post-­‐treatment	  and	   44	  %	   at	   6-­‐month	   follow-­‐up.	   At	   pre-­‐treatment,	   14	   (41	  %)	   of	   the	   patients	  fulfilled	  at	  least	  one	  DSM-­‐diagnosis	  (e.g.	  dysthymia,	  panic	  disorder,	  agoraphobia,	  and	  generalized	  anxiety	  disorder).	  Of	  the	  14	  patients	  diagnosed	  with	  a	  disorder	  at	  pre-­‐treatment,	  6	  (42%)	  and	  9	  (64%)	  no	  longer	  fulfilled	  diagnostic	  criteria	  at	  post-­‐treatment	  and	  follow-­‐up,	  respectively.	  As	  judged	  by	  the	  CGI,	  22	  (65%)	  and	  21	  (62%)	  were	  considered	  much	  or	  very	  much	  improved	  at	  post-­‐treatment	  and	  follow-­‐up,	  respectively.	  
3.4.6 METHODOLOGICAL	  CONSIDERATIONS	  This	  study	  did	  not	  include	  a	  control	  group,	  which	  limits	  the	  validity	  of	  the	  trial.	  However,	  in	  a	  review	  of	  CBT	  for	  IBS,	  Blanchard	  found	  that	  in	  15	  of	  16	  trials	  CBT	  was	   superior	   to	   a	  waiting	   list	   or	   treatment	   as	   usual	   control	   group	   (202).	   This	  indicates	   that	   active	   treatments	   have	   effects	   beyond	   those	   of	   time.	   Our	  recruitment	  method	   also	   limits	   the	   generalizability	   of	   the	   results.	   Participants	  were	  referred	  by	  gastroenterologists	  who	  may	  have	  selected	  patients	  on	  basis	  of	  perceived	  suitability	  for	  a	  psychological	  treatment.	  Thus,	  the	  study	  did	  probably	  not	   include	   a	   representative	   sample	   of	   IBS	   patients.	   The	   psychiatrist	   who	  assessed	   the	   patients	   is	   part	   of	   the	   research	   team	   and	  may	   have	   been	   biased	  towards	   detecting	   improvement	   after	   treatment.	   An	   independent	   assessor	  would	  have	  been	  preferable.	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3.5 STUDY	  II	  
3.5.1 PARTICIPANTS	  Participants	  were	  eligible	   for	  the	  study	  if	   they	  declared	  to	  have	  had	  a	  previous	  diagnosis	  of	   IBS	  established	  by	  a	  physician	  and	  if	   they	  presently	   fulfilled	  Rome	  III	   criteria	   for	   IBS	   (12).	   The	   study	   did	   not	   include	   a	   gastroenterological	  examination	  and	  we	  therefore	  used	  telephone	  interviews	  to	  confirm	  diagnostic	  criteria	   and	   exclude	   patients	  with	   symptoms	   that	   in	   a	   live	   care	   setting	  would	  have	  rendered	  a	  somatic	  investigation	  to	  rule	  out	  organic	  disease.	  Patients	  with	  suicide	   ideation	   or	   severe	   depressive	   symptoms,	   substance	   dependence,	   or	  psychiatric	   disorders	  were	   also	   excluded.	   Participants	  were	   recruited	   through	  self-­‐referral.	   Information	   about	   the	   studies	   was	   spread	   to	   websites	   and	  newspapers.	   Gastroenterological	   clinics	   located	   in	   Stockholm	   were	   also	  informed	  about	  the	  studies.	  The	  study	  included	  85	  participants.	  
3.5.2 INTERVENTIONS	  Participants	   were	   randomized	   to	   10	   weeks	   of	   ICBT	   (n=42)	   or	   a	   waiting	   list	  (n=43).	   The	   online	   therapists	  were	  2	   graduate	  psychology	   students	   in	   the	   last	  term	  of	  the	  five-­‐year	  psychology	  program.	  They	  had	  completed	  clinical	  training	  including	  supervised	  psychological	  treatment	  and	  clinical	  placement.	  They	  spent	  a	  mean	  of	  16.5	  minutes	  (sd=8.5)	  per	  week	  and	  participant	  during	  the	  treatment.	  We	   had	   the	   ambition	   to	   exert	   some	   control	   over	   the	   effects	   of	   attention	   and	  weekly	   activity	   in	   the	   study.	   Participants	   randomized	   to	   the	  waiting	   list	   were	  therefore	   given	   access	   to	   an	   online	   discussion	   forum	   (separate	   from	   the	   one	  used	   by	   the	   treatment	   intervention)	   where	   suggestions	   about	   general	  discussions	  regarding	  IBS	  were	  given.	  Participants	  were	  also	  allowed	  to	  initiate	  contact	  with	  an	  online	   therapist	   if	   they	  wished	   to	   receive	  general	   support,	  but	  were	   offered	   no	   CBT-­‐based	   advice	   on	   how	   to	   handle	   IBS	   symptoms	   or	  psychological	   distress.	   Besides	   sending	   an	   introductory	  message,	   the	   therapist	  did	   not	   initiate	   contact	   with	   participants	   on	   the	   waiting	   list.	   However,	   the	  activity	  of	  the	  waiting	  list	  participants	  in	  the	  discussion	  forums	  and	  utilization	  of	  therapist	  contact	  was	  almost	  negligible.	  
3.5.3 ASSESSMENTS	  The	   assessments	   included	   the	   GI	   symptom	   diary,	   GSRS-­‐IBS,	   IBS-­‐QOL,	   VSI,	  MADRS-­‐S,	   and	   the	   Sheehan	   disability	   scales.	   These	  were	   administered	   at	   pre-­‐treatment	   and	   post-­‐treatment	   for	   both	   groups.	   At	   3-­‐month	   follow-­‐up	   the	  treatment	   group	   also	   completed	   the	   GSRS-­‐IBS,	   IBS-­‐QOL,	   and	   VSI.	   After	   two	  weeks	   of	   treatment,	   the	   treatment	   group	   completed	   the	   treatment	   credibility	  scale.	  
3.5.4 ANALYSIS	  We	  used	  2x2	   repeated	  measures	  ANOVA	  and	   calculated	   the	   interaction	   effects	  between	   group	   and	   time	   to	   test	   for	   improvements	   in	   the	   treatment	   group	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compared	   to	   the	   waiting	   list.	   The	   proportion	   of	   participants	   who	   had	   a	   CPSR	  score	   ≥	   0.5	   post-­‐treatment	  was	   calculated.	  We	   also	   examined	   the	   relationship	  between	   completing	   the	   treatment	   and	   the	   rated	   treatment	   credibility.	  Dependent	   t-­‐tests	   were	   used	   to	   examine	   if	   treatment	   gains	   were	   maintained	  from	  post-­‐treatment	  to	  3-­‐month	  follow-­‐up	  for	  the	  treatment	  condition.	  
3.5.5 RESULTS	  Thirty-­‐eight	  of	  42	  (90%)	   in	   the	  treatment	  group	  completed	  the	  post-­‐treatment	  and	   3-­‐month	   follow-­‐up	   assessments	   and	   all	   43	   (100%)	   in	   the	   waiting	   list	  completed	  the	  post-­‐treatment	  assessment.	  Except	   for	   constipation,	   all	   interaction	  effects	  were	  significant.	  Large	  between-­‐groups	   effects	   were	   observed	   on	   primary	   symptoms,	   bloating,	   GSRS-­‐IBS,	   and	  IBS-­‐QOL.	   Moderate	   effects	   were	   observed	   on	   pain	   and	   the	   VSI.	   The	   between-­‐groups	  effects	  on	  the	  MADRS-­‐S	  and	  Sheehan	  disability	  scales	  were	  low.	  Using	  a	  CPSR	  score	  ≥	  0.5	  as	  measure	  of	  clinically	  significant	  symptom	  reduction,	  17	  of	  42	  (40%)	   in	   the	   treatment	   condition	   and	   1	   of	   43	   (2	  %)	   in	   the	   waiting	   list	   were	  improved,	   a	   significant	   difference.	   All	   improvements	   in	   the	   treatment	   group	  were	  maintained	  at	  the	  3-­‐month	  follow-­‐up.	  When	   comparing	   the	   treatment	   credibility	   scores	   of	   the	   29	   participants	   who	  completed	   the	   treatment	   and	   the	   11	   who	   did	   not	   complete	   the	   treatment,	   a	  significant	   difference	   was	   revealed,	   with	   a	   large	   between-­‐groups	   effect	   size	  (Cohen’s	  d	  =	  0.92).	  
3.5.6 METHODOLOGICAL	  CONSIDERATIONS	  In	  this	  study,	  we	  did	  not	   include	  a	  proper	  diagnostic	  procedure	  but	  relied	  on	  a	  previous	  diagnosis	   that	  was	  confirmed	   in	  a	   telephone	   interview.	  Therefore,	  we	  cannot	  be	  sure	  that	  all	  participants	  actually	  fulfilled	  Rome	  III	  criteria	  for	  IBS.	  The	  use	   of	   self-­‐referral	   also	   limits	   the	   generalizability	   of	   the	   study.	   We	   included	  limited	   therapist	   contact	   and	   an	   online	   discussion	   forum	   in	   the	   waiting	   list	  condition	  to	  exert	  some	  control	  over	  the	  effects	  of	  attention.	  But	  the	  activity	  in	  the	  waiting	   list	   was	   negligible.	   An	   active	   control	   group	   that	   included	   credible	  treatment	   interventions	   would	   have	   been	   preferable	   to	   control	   for	   the	   non-­‐specific	  effects	  of	  a	  psychological	  treatment.	  
3.6 STUDY	  III	  
3.6.1 PARTICIPANTS	  In	   study	   III	   all	   participants	   from	   study	   II	   were	   contacted	   for	   follow-­‐up	  assessments.	   Within	   study	   II	   they	   had	   been	   randomized	   to	   either	   ICBT	   or	  waiting	  list.	  After	  the	  conclusion	  of	  study	  II	  the	  waiting	  list	  was	  crossed	  over	  to	  treatment.	   Thus,	   at	   the	   time	  of	   follow-­‐up,	   all	   participants	   in	   study	   II	   had	  been	  offered	  ICBT.	  Seventy-­‐five	  of	  the	  original	  study’s	  85	  (88%)	  participants	  agreed	  to	  participate	   in	   the	   follow-­‐up.	  The	  original	   treatment	   group	  was	   followed	  up	  18	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months	  after	  treatment	  and	  the	  waiting	  list	  was	  followed	  up	  at	  15	  months	  after	  completing	  the	  treatment	  (mean	  16.4	  months).	  
3.6.2 ASSESSMENTS	  The	   assessments	   included	   the	  GSRS-­‐IBS,	   IBS-­‐QOL,	   VSI,	   and	   the	   adequate	   relief	  question.	  
3.6.3 ANALYSIS	  Within-­‐group	   effect	   sizes	   were	   calculated	   for	   the	   improvement	   from	   pre-­‐treatment	   to	   follow-­‐up.	   We	   used	   dependent	   t-­‐tests	   to	   assess	   whether	   these	  improvements	   were	   significant	   and	   to	   test	   if	   treatment	   gains	   were	   sustained	  from	  post-­‐treatment	   to	   the	   follow-­‐up.	  The	  proportion	  of	  participants	  reporting	  adequate	  relief	  was	  calculated.	  Missing	  follow-­‐up	  values	  were	  replaced	  with	  pre-­‐treatment	  values,	  meaning	  that	  the	  calculations	  also	  included	  the	  10	  participants	  from	  Study	  II	  who	  did	  not	  participate	  in	  Study	  III.	  These	  calculations	  were	  made	  separately	   for	   the	  original	   study’s	   treatment	  group	  and	  waiting	   list,	  which	  had	  been	   crossed	   over	   to	   treatment.	   We	   also	   examined	   if	   participants	   who	   had	  completed	   the	   whole	   treatment	   had	   better	   long-­‐term	   outcomes	   than	  participants	  who	  had	  not	  completed	  the	  treatment.	  	  
3.6.4 RESULTS	  There	   were	   significant	   improvements	   from	   pre-­‐treatment	   to	   follow-­‐up	   on	   all	  measures,	  the	  GSRS-­‐IBS,	  IBS-­‐QOL,	  and	  VSI,	  and	  improvements	  were	  maintained	  from	   post-­‐treatment	   to	   follow-­‐up.	   The	   within-­‐group	   effect	   sizes	   from	   pre-­‐treatment	  to	  follow-­‐up	  were	  large	  on	  the	  GSRS-­‐IBS	  and	  IBS-­‐QOL	  and	  near-­‐large	  on	   the	  VSI.	   At	   follow-­‐up,	   52%	  of	   participants	   in	   the	   original	   study’s	   treatment	  group	  and	  65%	  of	  the	  waiting	  list	  participants	  reported	  adequate	  relief	  (59%	  of	  the	  total	  sample).	  When	  participants	  who	  had	  completed	  the	  treatment	  (n=62)	  were	  compared	  to	  the	   participants	   who	   had	   not	   completed	   the	   treatment	   (n=13),	   there	   were	  significant	   differences	   on	   the	   IBS-­‐QOL	   (between-­‐groups	   d=0.84)	   and	   VSI	  (d=0.72).	   The	   difference	   between	   the	   groups	   on	   the	   GSRS-­‐IBS	  was	   borderline	  significant	  (p<.06	  and	  d=0.68).	  Furthermore,	  a	  significantly	  larger	  proportion	  of	  completers	  reported	  adequate	  relief,	  74%	  compared	  with	  33%.	  
3.6.5 METHODOLOGICAL	  CONSIDERATIONS	  Since	   the	   waiting	   list	   in	   study	   II	   had	   been	   offered	   treatment	   we	   could	   not	  compare	  the	  long-­‐term	  effects	  with	  a	  control	  group.	  Crossing	  over	  patients	  from	  waiting	  list	  to	  treatment	  also	  introduces	  some	  methodological	  problems	  because	  of	   possible	   interaction	   effects	   between	   being	   on	   a	   waiting	   list	   and	   then	  participating	   in	   treatment.	   However,	   there	   did	   not	   seem	   to	   be	   any	   major	  differences	  between	  the	  original	  study’s	  treatment	  group	  and	  waiting	  list	  at	  the	  follow-­‐up.	  This	  indicates	  small,	  if	  any,	  interaction	  effects	  in	  the	  waiting	  list.	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3.7 STUDY	  IV	  
3.7.1 PARTICIPANTS	  The	  participants	  in	  study	  V	  were	  recruited	  consecutively	  at	  a	  gastroenterological	  clinic	   in	  Stockholm.	  Participants	  were	  eligible	   for	   the	   study	   if	   they	   fulfilled	   the	  Rome	   III	   criteria	   for	   IBS	   (12),	   were	   between	   18	   and	   65	   years	   old,	   had	   no	  presence	  of	  current	  or	  previous	  inflammatory	  bowel	  disease,	  did	  not	  suffer	  from	  such	   severe	  diarrhea	   that	   symptom-­‐modifying	   antidepressants	  were	   judged	   to	  be	   the	   treatment	   of	   first	   choice,	   and	   if	   they	  were	  willing	   to	   participate	   in	   the	  study.	  As	  our	   aim	  was	   to	   recruit	  patients	  who	  attended	  a	   regular	   gastroenterological	  clinic	   and	  minimize	   selection	  bias,	   no	   information	  about	   the	   study	  was	   spread	  through	   advertisements	   or	   to	   other	   caregivers	   in	   Stockholm.	   All	   included	  participants	  were	   given	   standardized	   information	   about	   IBS	   and	   basic	   dietary	  and	   lifestyle	   advice	   on	   how	   to	   manage	   their	   IBS	   (i.e.,	   treatment	   as	   usual).	   If	  appropriate	   they	   were	   also	   given	   information	   about	   over-­‐the-­‐counter	   drugs	  and/or	  prescribed	  medication.	  Of	  117	  patients	  who	  were	  eligible	  and	  considered	  for	  the	  study,	  11	  were	  prescribed	  antidepressants,	  12	  declined	  participation,	  12	  were	   excluded	   for	   other	   reasons,	   5	   patients	   could	   not	   be	   reached	   within	   the	  recruitment	   period,	   15	   patients	   were	   included	   but	   dropped	   out	   before	  randomization,	  and	  62	  were	  randomized.	  
3.7.2 INTERVENTIONS	  The	  62	  participants	  were	  randomized	  to	  10	  weeks	  of	  ICBT	  (n=30)	  or	  a	  waiting	  list	   (n=32).	  Two	  clinical	  psychologists	  managed	   the	  online	   therapeutic	   contact.	  The	   therapists	   spent	   a	   mean	   of	   7.3	   minutes	   (sd=5.2)	   per	   patient	   in	   the	   ICBT	  condition	   and	   week.	   Similarly	   to	   study	   II,	   the	   waiting	   list	   included	   a	   limited	  supportive	   therapist	   contact	   and	   an	   online	   discussion	   forum.	   Also	   similarly	   to	  study	  II,	  the	  activity	  in	  the	  waiting	  list	  was	  almost	  negligible.	  
3.7.3 ASSESSMENTS	  The	   assessments	   included	   the	   GSRS-­‐IBS,	   IBS-­‐QOL,	   VSI,	   MADRS-­‐S,	   and	   the	  Sheehan	  disability	   scales.	  These	  were	  administered	  at	  pre-­‐treatment	  and	  post-­‐treatment	  for	  both	  groups	  and	  at	  12-­‐month	  follow-­‐up	  for	  the	  treatment	  group.	  
3.7.4 ANALYSIS	  Main	  outcome	  variables	  were	  analyzed	  using	  a	  linear	  mixed	  effects	  model	  fitted	  with	   full	   information	   maximum	   likelihood	   estimation	   (203).	   The	   superior	  qualities	   regarding	  missing	   data	   as	   well	   as	   increased	   power	   compared	   to	   the	  traditional	  repeated	  measures	  ANOVA	  make	  mixed	  models	  the	  preferred	  choice	  for	   longitudinal	   data	   analysis	   (204).	   We	   used	   the	   fixed	   effects	   interaction	  between	  group	  and	   time	   to	  examine	   the	  difference	   in	   rates	  of	   change	  between	  the	  treatment	  condition	  and	  waiting	  list	  from	  pre-­‐	  to	  post-­‐treatment.	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3.7.5 RESULTS	  Twenty-­‐three	  of	  30	  (77%)	  in	  the	  treatment	  group	  completed	  the	  post-­‐treatment	  and	   20	   of	   30	   (67%)	   completed	   the	   12-­‐month	   follow-­‐up.	   Twenty-­‐eight	   of	   32	  (88%)	   of	   the	   participants	   in	   the	   waiting	   list	   completed	   the	   post-­‐treatment	  assessment.	  Significant	  interaction	  effects	  from	  the	  mixed	  models	  analyses	  were	  obtained	  on	  the	   GSRS-­‐IBS,	   IBS-­‐QOL,	   VSI,	   and	   Sheehan	   disability	   scales	   but	   not	   on	   the	  MADRS-­‐S.	   On	   the	   GSRS-­‐IBS,	   IBS-­‐QOL,	   and	   VSI	   the	   between-­‐groups	   effects	   at	  post-­‐treatment	  were	  about	  large	  and	  on	  the	  Sheehan	  disability	  scales	  the	  effect	  was	   small.	   All	   improvements	   in	   the	   treatment	   group	   were	   maintained	   at	   12-­‐month	  follow-­‐up.	  
3.7.6 METHODOLOGICAL	  CONSIDERATIONS	  This	  study	  addressed	  the	  limitations	  regarding	  recruitment	  in	  studies	  I	  and	  II	  by	  consecutively	   recruiting	   a	   clinical	   sample.	   However,	   although	   we	   had	   the	  ambition	  of	  conducting	  a	  study	  in	  clinical	  setting,	  many	  properties	  of	  the	  study	  are	   not	   part	   of	   a	   clinical	   setting.	   The	   use	   of	   a	   waiting	   list	   and	   extensive	  assessments	  may	  very	  well	  have	  made	  some	  patients	  less	  inclined	  to	  volunteer	  for	  the	  study	  or	  drop	  out	  after	  inclusion.	  Furthermore,	  a	  sample	  of	  patients	  at	  a	  gastroenterological	  clinic	  may	  not	  be	  generalizable	  to	  the	  whole	  IBS	  population.	  Similarly	  to	  study	  II,	  we	  had	  almost	  no	  activity	  in	  the	  waiting	  list,	  meaning	  that	  it	  did	   not	   provide	   any	   control	   over	   the	   non-­‐specific	   effects	   of	   a	   psychological	  treatment.	  
3.8 STUDY	  V	  
3.8.1 PARTICIPANTS	  The	   recruitment	   procedure	   in	   study	   V	   was	   almost	   identical	   to	   study	   II.	   We	  spread	   information	   about	   the	   study	  on	   the	   internet	   and	   to	   gastroenterological	  clinics	   in	   Stockholm.	  Participants	  had	   to	  declare	   that	   they	  had	  been	  diagnosed	  with	   IBS	   when	   applying	   for	   the	   study.	   Rome	   III	   criteria	   were	   confirmed	   in	   a	  telephone	  interview	  and	  participants	  with	  alarm	  symptoms,	  suicide	  ideation,	  or	  severe	  depressive	  symptom	  or	  substance	  dependence	  were	  excluded.	  The	  study	  included	  195	  participants.	  
3.8.2 INTERVENTIONS	  Participants	   were	   randomized	   to	   ICBT	   (n=98)	   or	   internet-­‐delivered	   stress	  management	  (ISM;	  n=97).	  Both	  treatments	  lasted	  for	  10	  weeks.	  The	   stress	   management	   protocol	   was	   developed	   specifically	   for	   study	   V	   to	  ensure	  that	  relevant	  criteria	  for	  a	  credible	  control	  condition	  were	  met.	  The	  aim	  was	  to	  include	  elements	  that	  are	  common	  to	  all	  psychological	  interventions,	  e.g.	  a	   rationale	   for	   the	   interventions,	   acquisition	   and	   practice	   of	   new	   behaviors,	  expectancy	  of	   improvement,	  and	   therapeutic	  alliance	   (205).	  Participants	   in	   the	  study	   were	   informed	   that	   they	   would	   be	   randomized	   to	   one	   of	   two	   different	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psychological	   treatments	   that	   were	   known	   to	   be	   effective	   in	   treating	   IBS,	   but	  they	  were	  not	  aware	  of	  the	  differences	  between	  the	  treatments.	  Stress	   management	   is	   based	   on	   the	   common	   notion	   that	   IBS	   symptoms	   are	  exacerbated	  by	  daily	  stressors	  (65)	  and	  that	  better	  coping	  with	  these	  stressors	  should	  alleviate	  the	  burden	  of	  symptoms.	  The	  treatment	  interventions	  were:	  1)	  Progressive	   applied	   relaxation,	   used	   to	   put	   the	   body	   in	   a	   state	   of	   immediate	  relaxation	   in	   response	   to	   IBS	   symptoms	   and	  psychological	   distress.	   2)	  Dietary	  strategies,	  such	  as	  eating	  small	  but	  regular	  meals,	  taking	  enough	  time	  to	  eat,	  and	  becoming	  more	  aware	  of	  associations	  between	  certain	  foods	  and	  IBS	  symptoms.	  3)	   Problem	   solving	   strategies	   used	   to	   divide	   daily	   hassles	   into	   smaller	   and	  solvable	   problems.	   4)	   Advice	   on	   how	   to	   increase	   the	   quality	   of	   sleep	   using	  common	   sleep	  hygiene	   strategies.	   The	   stress	  management	  did	  not	   include	   any	  elements	  that	  encouraged	  the	  participants	  to	  engage	  in	  activities	  despite	  having	  symptoms	  (e.g.,	  exposure)	  or	  to	  reduce	  their	  symptom	  controlling	  activities.	  	  We	   used	   6	   therapists	   in	   the	   study,	   4	   graduate	   psychology	   students	   and	   two	  clinical	  psychologists.	  The	  therapists	  were	  randomly	  assigned	  participants	  from	  both	  conditions	  in	  equal	  numbers	  to	  control	  for	  any	  therapist-­‐specific	  effects.	  In	  the	   ICBT	   group	   the	   therapists	   spent	   a	   mean	   of	   10.1	   minutes	   (sd=7.5)	   per	  participant	  and	  week	  writing	  messages	  to	  the	  participants	  and	  in	  the	  ISM	  group	  they	  spent	  7.8	  minutes	  (sd=6.2)	  per	  week	  and	  participant.	  
3.8.3 ASSESSMENTS	  The	  assessments	  included	  the	  GSRS-­‐IBS,	  IBS-­‐QOL,	  VSI,	  CSFBD,	  HADS,	  and	  PSS	  at	  pre-­‐treatment,	   post-­‐treatment	   and	   6-­‐month	   follow-­‐up	   for	   both	   groups.	   The	  adequate	   relief	   question	  was	   asked	   at	   post-­‐treatment	   and	   6-­‐month	   follow-­‐up.	  During	  treatment,	  the	  treatment	  credibility	  scale	  was	  administered	  after	  2	  and	  5	  weeks	  and	  the	  working	  alliance	  inventory	  as	  administered	  after	  4	  weeks.	  
3.8.4 ANALYSIS	  We	  used	  the	  same	  analytic	  strategy	  as	  in	  study	  IV,	  a	  linear	  mixed	  effects	  model	  fitted	  with	   full	   information	  maximum	   likelihood	  estimation.	  We	  used	   the	   fixed	  effects	  interaction	  between	  group	  and	  time	  to	  examine	  the	  difference	  in	  rates	  of	  change	  between	  the	  ICBT	  and	  ISM	  from	  pre-­‐treatment,	  via	  post-­‐treatment,	  to	  6-­‐month	  follow-­‐up.	  In	   study	   V	  we	   also	   examined	   if	   the	   two	   treatments,	   ICBT	   and	   ISM,	   differed	   in	  terms	  of	  credibility	  and	  induction	  of	  expectation	  of	  improvement	  (as	  measured	  by	  the	  treatment	  credibility	  scale),	  therapeutic	  alliance	  with	  the	  online	  therapist	  (as	  measured	  by	  the	  working	  alliance	  inventory),	  or	  the	  amount	  of	  attention	  the	  participants	   received	   (as	   measured	   by	   the	   number	   of	   messages	   the	   online	  therapists	  sent).	  The	  proportions	  of	  participants	  reporting	  adequate	  relief	  in	  the	  two	   treatments	   at	   post-­‐treatment	   and	  6-­‐month	   follow-­‐up	  were	   also	   calculated	  and	  compared.	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3.8.5 RESULTS	  Ninety-­‐seven	  of	  98	  (99%)	  ICBT	  participants	  and	  94	  of	  97	  (97%)	  ISM	  participants	  completed	  the	  post-­‐treatment	  assessment	  and	  87	  (89%)	  of	  the	  ICBT	  participants	  and	  82	  (85%)	  of	  the	  ISM	  participants	  completed	  the	  6-­‐month	  follow-­‐up.	  There	  was	   a	   significant	   effect	   of	   group	   and	   time	   over	   the	   post-­‐treatment	   and	  follow-­‐up	   periods	   in	   the	   mixed	   models	   analyses	   on	   all	   IBS-­‐specific	   outcome	  measures	  (GSRS-­‐IBS,	   IBS-­‐QOL,	  VSI,	  and	  CSFBD)	  but	  not	  on	   the	  general	  distress	  measures	   (HADS	   anxiety	   and	   depression	   and	   PSS).	   The	   between-­‐groups	   effect	  sizes	   were	   in	   the	   small	   to	   moderate	   range	   at	   post-­‐treatment	   and	   follow-­‐up.	  Significantly	  more	  participants	  in	  the	  ICBT	  group	  than	  in	  the	  ISM	  group	  reported	  adequate	  relief	  at	  follow-­‐up,	  65%	  vs.	  44%.	  There	  were	   no	   differences	   on	   the	   process	  measures	   (the	   treatment	   credibility	  scale	   and	  working	   alliance	   inventory)	   or	   in	   the	   number	   of	  messages	   received	  from	  the	  online	  therapist	  between	  the	  groups.	  
3.8.6 METHODOLOGICAL	  CONSIDERATIONS	  The	   study	   did	   not	   employ	   a	   proper	   gastroenterological	   examination	   and	  included	   self-­‐referred	   participants.	   Therefore,	   the	   limitations	   regarding	  diagnostic	  procedure	  and	  generalizability	   in	  study	   II	  also	  pertain	   to	   this	   study.	  The	  research	  group	  is	  also	  biased	  towards	  favoring	  the	  ICBT	  treatment	  over	  the	  ISM	   treatment.	  This	  may	  have	   affected	   the	   therapists	   in	   their	   contact	  with	   the	  patients	  but	  also	   the	   interpretation	  and	  presentation	  of	   the	  data.	  However,	  we	  believe	  that	  the	  primary	  goal	  of	  the	  study,	  to	  control	  for	  the	  non-­‐specific	  effects	  of	  a	  psychological	  treatment,	  was	  met	  despite	  this	  bias.	  
3.9 SUMMARY	  OF	  THE	  STUDIES	  In	   the	   studies	   different	   data	   reporting	   and	   analysis	   strategies	   and	   different	  comparison	   groups	   were	   used.	   This	   makes	   it	   difficult	   to	   compare	   the	   results	  between	   the	   different	   conditions	   and	   get	   an	   overall	   impression	   of	   the	  effectiveness	   of	   exposure-­‐based	   CBT.	   To	   allow	   for	   such	   comparison	   and	  evaluation	   the	   pre-­‐	   and	   post-­‐treatment	   scores	   for	   the	   IBS-­‐specific	   measures	  shared	   between	   two	   or	  more	   of	   the	   studies	   (the	   GI	   symptom	  diary,	   GSRS-­‐IBS,	  IBS-­‐QOL,	   and	   VSI)	   were	   extracted	   from	   studies	   I,	   II,	   IV,	   and	   V.	   Within-­‐group	  effect	  sizes,	  comparing	  post-­‐treatment	  and	  pre-­‐treatment,	  were	  calculated	  using	  three	   different	   strategies	   to	   handle	   missing	   data.	   1)	   Using	   all	   available	   data,	  meaning	  that	  participants	  who	  dropped	  out	  of	  the	  studies	  before	  post-­‐treatment	  still	   contributed	   to	   the	   pre-­‐treatment	   values.	   2)	   Using	   only	   data	   from	  participants	  who	   completed	   both	   the	   pre-­‐	   and	   post-­‐treatment	   assessments.	   3)	  Replacing	   missing	   post-­‐treatment	   values	   with	   pre-­‐treatment	   values	   (last	  observation	   carried	   forward).	   Dependent	   t-­‐tests	   were	   performed	   to	   test	   the	  significance	  of	  these	  pre-­‐	  to	  post-­‐treatment	  improvements.	  	  Table	  4	  displays	   observed	  pre-­‐	   and	  post-­‐treatment	   scores	   for	   the	  GI	   symptom	  diary,	   GSRS-­‐IBS,	   IBS-­‐QOL,	   and	   VSI	   for	   all	   conditions	   in	   the	   treatment	   studies.	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Looking	  at	  the	  results	  of	  exposure-­‐based	  CBT	  the	  effect	  sizes	  on	  all	  measures	  are	  centered	   on	   0.9-­‐1.0	   in	   all	   studies.	   The	   large	   dropout	   in	   study	   IV	   makes	   it	   an	  exception	  with	  lower	  conservative	  estimates	  of	  effect	  sizes	  on	  GSRS-­‐IBS	  and	  IBS-­‐QOL.	  Study	  I,	  which	  evaluated	  group	  treatment,	  has	  markedly	  higher	  effects	  on	  the	  IBS-­‐QOL	  and	  VSI	  than	  the	  internet-­‐delivered	  treatments.	  In	   study	   V	   it	   was	   concluded	   that	   the	   internet-­‐delivered	   CBT	   was	   superior	   to	  internet-­‐delivered	   stress	  management,	  which	   is	   also	   clear	   in	   this	  presentation.	  The	  within-­‐group	  effect	  sizes	  are	  about	  0.5	  on	  all	  measures	  for	  that	  treatment.	  Participants	  on	  waiting	  lists	  (studies	  II	  and	  IV)	  did	  not	  improve	  on	  any	  outcomes	  during	  their	  stay	  on	  the	  waiting	   list.	  The	  only	  change	  that	  was	  observed	  was	  a	  significant	  deterioration	  on	  the	  IBS-­‐QOL	  in	  the	  study	  IV	  waiting	  list.	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Table	  4.	  Observered	  pre-­‐	  and	  post-­‐treatment	  scores	  in	  Studies	  I,	  II,	  IV,	  and	  V	  with	  
within-­‐group	  effect	  sizes.	  	  





	   Within-­‐group	  
effect	  size	  
	  	  Study	  -­‐	  condition	   n	   m	   sd	   	   n	   m	   sd	   	   Missing	   	   Obs	   Comp	   LOCF	  
GI	  symptom	  diary♫	  	  	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	  Study	  I	  -­‐	  GCBT	   34	   5.1	   2.7	   	   33	   2.9	   2.8	   	   3%	   	   0.83*	   0.79*	   0.71*	  
	  	  Study	  II	  -­‐	  ICBT	   42	   5.7	   2.8	   	   34	   3.1	   2.8	   	   19%	   	   0.95*	   0.81*	   0.61*	  
	  	  Study	  II	  -­‐	  WL	   43	   5.2	   2.5	   	   43	   5.2	   2.6	   	   0%	   	   -­‐0.04	   -­‐0.04	   -­‐0.04	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	  
GSRS-­‐IBS	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	  Study	  II	  -­‐	  ICBT	   42	   36.1	   9.4	   	   41	   21.4	   13.6	   	   2%	   	   1.27*	   1.30*	   1.28*	  
	  	  Study	  IV	  -­‐	  ICBT	   30	   31.6	   11.1	   	   22	   18.8	   9.6	   	   27%	   	   1.24*	   1.09*	   0.61*	  
	  	  Study	  V	  -­‐	  ICBT	   98	   34.5	   10.5	   	   96	   23.3	   12.7	   	   2%	   	   0.97*	   0.98*	   0.97*	  
	  	  Study	  V	  -­‐	  ISM	   97	   34.3	   9.4	   	   90	   28.1	   12.4	   	   7%	   	   0.57*	   0.56*	   0.54*	  
	  	  Study	  II	  -­‐	  WL	   43	   36.6	   11.8	   	   43	   34.3	   12.6	   	   0%	   	   0.19	   0.19	   0.19	  
	  	  Study	  IV	  -­‐	  WL	   32	   26.7	   11.8	   	   28	   27.5	   14.4	   	   13%	   	   -­‐0.06	   -­‐0.02	   -­‐0.02	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	  
IBS-­‐QOL	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	  Study	  I	  -­‐	  GCBT	   34	   51.9	   20.2	   	   33	   77.5	   19.1	   	   3%	   	   1.30*	   1.28*	   1.11*	  
	  	  Study	  II	  -­‐	  ICBT	   42	   51.8	   19.1	   	   38	   71.8	   19.9	   	   10%	   	   1.02*	   0.98*	   0.89*	  
	  	  Study	  IV	  -­‐	  ICBT	   30	   67.4	   20.9	   	   23	   82.6	   13.4	   	   23%	   	   0.89*	   0.69*	   0.39*	  
	  	  Study	  V	  -­‐	  ICBT	   98	   57.1	   19.1	   	   97	   75.7	   17.7	   	   1%	   	   1.01*	   1.01*	   1.00*	  
	  	  Study	  V	  -­‐	  ISM	   97	   55.5	   18.9	   	   94	   65.7	   21.1	   	   3%	   	   0.51*	   0.53*	   0.51*	  
	  	  Study	  II	  -­‐	  WL	   43	   53.8	   18.9	   	   43	   53.0	   21.3	   	   0%	   	   -­‐0.04	   -­‐0.04	   -­‐0.04	  
	  	  Study	  IV	  -­‐	  WL	   32	   75.5	   18.8	   	   28	   67.0	   22.8	   	   13%	   	   -­‐0.41*	   -­‐0.33*	   -­‐0.30*	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	  
VSI	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	  Study	  I	  -­‐	  GCBT	   34	   47.7	   18.3	   	   33	   24.0	   15.6	   	   3%	   	   1.40*	   1.36*	   1.24*	  
	  	  Study	  II	  -­‐	  ICBT	   42	   44.1	   15.1	   	   38	   30.2	   17.8	   	   10%	   	   0.84*	   0.87*	   0.81*	  
	  	  Study	  IV	  -­‐	  ICBT	   30	   32.5	   18.0	   	   22	   14.8	   15.1	   	   27%	   	   1.07*	   1.05*	   0.70*	  
	  	  Study	  V	  -­‐	  ICBT	   98	   38.5	   16.8	   	   96	   24.9	   16.9	   	   2%	   	   0.80*	   0.79*	   0.78*	  
	  	  Study	  V	  -­‐	  ISM	   97	   38.6	   16.4	   	   91	   30.5	   16.8	   	   6%	   	   0.48*	   0.52*	   0.49*	  
	  	  Study	  II	  -­‐	  WL	   43	   43.3	   17.5	   	   43	   41.9	   18.7	   	   0%	   	   0.07	   0.07	   0.07	  
	  	  Study	  IV	  -­‐	  WL	   32	   27.3	   16.1	   	   28	   26.3	   17.5	   	   13%	   	   0.06	   0.19	   0.17	  
*p<.05	  for	  dependent	  t-­‐test.	  ♫Composite	  score	  of	  primary	  GI	  symptoms.	  Obs:	  Effect	  sizes	  calculated	  
on	  all	  available	  data.	  Comp:	  Effect	  sizes	  calculated	  only	  on	  participants	  completing	  both	  pre-­‐	  and	  
post-­‐treatment	  assessment.	  LOCF:	  Effect	  sizes	  with	  missing	  post-­‐treatment	  scores	  replaced	  with	  pre-­‐
treatment	  scores.	  GCBT:	  Exposure-­‐based	  group	  CBT.	  ICBT:	  Internet-­‐delivered	  exposure-­‐based	  CBT.	  
ISM:	  Internet-­‐delivered	  stress	  management.	  WL:	  Waiting	  list.	  	  
	  GCBT	  and	  ICBT	  effects	  sizes	  are	  framed.	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4. GENERAL	  DISCUSSION	  
4.1 INTERPRETATION	  OF	  RESULTS	  The	   aim	   of	   this	   thesis	   was	   to	   develop	   and	   evaluate	   an	   effective	   psychological	  treatment	  for	  IBS	  that	  can	  be	  made	  accessible	  to	  a	  large	  number	  of	  IBS	  patients.	  The	   means	   to	   achieve	   this	   aim	   were	   to	   develop	   an	   exposure-­‐based	   CBT	  treatment	  that	  emphasized	  acceptance	  and	  behavioral	   flexibility	   in	  response	  to	  IBS-­‐related	  experiences	  and	  deliver	  this	  treatment	  via	  the	  internet.	  Five	  studies	  were	   conducted	   to	   evaluate	   the	   effectiveness	   of	   these	  means	   in	   achieving	   the	  aim.	  In	  the	  first	  pilot	  study,	  the	  treatment	  was	  delivered	  in	  group	  format	  and	  in	  the	   following	   three	   treatment	   studies,	   it	   was	   delivered	   via	   internet.	   We	  hypothesized	  that	  the	  treatment	  would	  lead	  to	  improvements	  in	  IBS	  symptoms,	  quality	  of	  life,	  and	  GI	  symptom-­‐specific	  anxiety.	  In	   all	   four	   treatment	   studies	   these	   hypotheses	  were	   corroborated.	   In	   terms	   of	  effect	   sizes,	   the	   exposure-­‐based	   CBT	   generally	   produced	   large	   within-­‐group	  effects	   and	   large	   between-­‐groups	   effects	   when	   waiting	   list	   was	   used	   as	  comparison	   condition.	   We	   used	   different	   definitions	   of	   treatment	   response	  between	  the	  studies.	  A	  50%	  reduction	  of	  symptoms	  was	  used	  in	  studies	  I	  and	  II	  and	   gave	   a	   response	   rate	   of	   40%	   and	   50%,	   respectively.	   Subjectively	   rated	  adequate	  relief	  was	  used	  in	  studies	  III	  and	  V	  and	  gave	  a	  response	  rate	  between	  52%	  and	  69%.	  In	  study	  IV	  we	  did	  not	  report	  a	  dichotomous	  response	  rate.	  It	  is	  difficult	   to	   judge	  which	  measure	  gives	   the	   “true”	  rate	  of	   treatment	  responders.	  However,	  it	  seems	  reasonable	  to	  conclude	  that	  at	  least	  50%	  of	  the	  patients	  who	  were	   included	   in	   these	   studies	   experienced	   a	   subjectively	   rated	   long-­‐term	  adequate	  relief	  of	  IBS-­‐related	  pain	  and	  discomfort.	  We	  also	  hypothesized	  that	  the	  treatment	  would	  lead	  to	  reductions	  in	  comorbid	  psychiatric	  problems,	  since	   it	  emphasized	  behavioral	   flexibility	   in	  the	  presence	  of	  aversive	  stimuli.	  This	  hypothesis	  was	  confirmed	  in	  study	  I,	  where	  64%	  of	  the	  participants	  who	  had	  fulfilled	  criteria	   for	  a	  DSM-­‐diagnosis	  before	  treatment	  no	  longer	  did	  so	  at	  6-­‐month	  follow-­‐up.	   In	  studies	  II,	   IV,	  and	  V	  this	  hypothesis	  was	  not	  explicit.	  However,	  significant	  reductions	  in	  depressive	  symptoms	  were	  noted	  in	  studies	  II	  and	  IV	  but	  with	  small	  effect	  sizes.	  In	  study	  V	  there	  was	  no	  difference	  between	  the	  two	  active	  treatment	  groups	  on	  the	  depression	  and	  anxiety	  scales,	  which	  could	  be	  interpreted	  as	  a	  contradiction	  of	  the	  hypothesis	  that	  the	  nature	  of	   the	   exposure-­‐based	   intervention	   leads	   to	   broad	   effects	   on	   mental	   health.	  However,	   since	   depression	   is	   not	   present	   in	   all	   IBS	   patients,	   calculating	   an	  overall	   reduction	   score	   introduces	   ceiling	   effects	   in	   attainable	   effects	   sizes.	  Proper	   investigation	  of	   this	  hypothesis	   in	   studies	   II,	   IV,	   and	  V	  would	   therefore	  require	  better	  analysis	  of	  the	  data.	  The	  effects	  on	  global	  functioning	  are	  similarly	  modest,	  with	  between-­‐groups	  effects	  of	  0.21	  and	  0.47	  compared	  to	  the	  waiting	  lists	   in	   studies	   II	   and	   IV,	   respectively.	   Again,	   this	   is	   probably	   due	   to	   a	   large	  spread	  in	  disability	  with	  many	  participants	  presenting	  with	  very	  little	  disability.	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The	   studies	   used	   3-­‐,	   6-­‐,	   12-­‐,	   15-­‐,	   and	   18-­‐month	   follow-­‐up	   periods	   and	   clearly	  show	  that	  treatment	  gains	  were	  maintained	  over	  time.	  This	  is	  in	  sharp	  contrast	  to	  pharmacological	  studies	  where	  the	  general	  rule	  is	  that	  discontinuation	  of	  the	  treatment	   leads	   to	   symptom	   relapse.	   With	   response	   rates	   over	   50%	   that	   are	  sustained	  over	  time,	  these	  studies	  show	  a	  definite	  advantage	  of	  exposure-­‐based	  CBT	   over	   pharmacological	   treatments.	   In	   study	   III,	   the	   long-­‐term	   effects	   of	  actually	  engaging	  in	  the	  treatment	  become	  clear	  when	  comparing	  the	  follow-­‐up	  scores	   for	  completers	  and	  non-­‐completers.	  On	  all	  outcome	  measures,	   including	  adequate	  relief,	  there	  were	  meaningful	  differences	  between	  the	  two	  groups.	  	  In	  light	  of	  the	  high	  societal	  costs	  of	  IBS	  we	  have	  made	  cost-­‐effectiveness	  analyses	  on	   data	   collected	   in	   studies	   II	   and	   III,	   which	   have	   been	   published	   separately	  (206).	  The	  analyses	  showed	  that	  compared	  to	  the	  waiting	  list	  the	  ICBT	  leads	  to	  cost	  reductions	  of	  $16,806	  per	  successfully	  treated	  patient	  and	  year.	  These	  cost	  reductions	  were	  mainly	  driven	  by	  reduced	  work	  loss	  and	  were	  maintained	  at	  15-­‐18-­‐month	  follow-­‐up.	  Study	  IV	  was	  designed	  to	  investigate	  the	  effectiveness	  and	  clinical	  utility	  of	  the	  treatment.	   We	   consecutively	   recruited	   patients	   from	   one	   gastroenterological	  clinic.	  In	  the	  discussion	  of	  the	  paper	  describing	  study	  IV	  we	  argue	  that	  the	  study	  shows	  that	  the	  exposure-­‐based	  CBT	  may	  be	  effective	  for	  a	   larger	  proportion	  of	  IBS	  patients	  than	  studies	  I	  and	  II	  indicated.	  This	  discussion	  is	  based	  on	  the	  fact	  that	  the	  participants	  included	  in	  the	  study	  had	  less	  impairment	  as	  measured	  by	  the	   VSI	   and	   IBS-­‐QOL	   than	   the	   participants	   in	   the	   previous	   studies.	   Since	  participants	   in	   those	   studies	   were	   referred	   and	   self-­‐referred	   it	   could	   be	  concluded	   that	   referring	   gastroenterologists	   and	   patients	   have	   higher	   cut-­‐offs	  regarding	   impairment	   than	   is	   necessary	   to	   achieve	   large	   improvements	   from	  treatment.	   However,	   I	   now	   believe	   that	   there	   are	   other	   explanations	   for	   this	  difference	   in	   impairment	   that	   do	   not	   support	   this	   conclusion.	   It	   could	   be	   that	  patients	  with	  more	  impairment	  are	  underrepresented	  in	  a	  consecutive	  sample	  of	  patients	  making	  their	  first	  visit	  at	  a	  gastroenterological.	  However,	  these	  patients	  would	  not	  be	  underrepresented	   in	  studies	  I	  and	  II,	   thus	   increasing	  the	  average	  impairment	  in	  those	  studies.	  I	   think	  that	   it	   is	  more	   interesting	  to	  use	  study	  IV	  to	  make	   inferences	  about	  the	  acceptability	   of	   the	   treatment	   in	   a	   clinical	   setting.	   Based	   on	   available	   data	   in	  paper	   IV,	   acceptability	   could	   be	   defined	   as	   the	   proportion	   of	   eligible	   patients	  who	  ended	  up	  completing	  the	  post-­‐treatment	  assessment.	  Of	  117	  patients	  who	  fulfilled	  eligibility	  criteria	  and	  were	  considered	  for	  the	  study,	  62	  were	  eventually	  randomized	   and	   of	   the	   30	   who	   were	   randomized	   to	   treatment,	   23	   (77%)	  participated	  in	  the	  post-­‐treatment	  assessment.	  Extrapolating	  the	  dropout-­‐rate	  in	  the	  treatment	  group	  to	  the	  whole	  randomized	  sample,	  48	  (77%	  of	  62)	  patients	  could	  be	  considered	  as	  treatment	  completers.	  The	  acceptance	  rate	  of	   ICBT	  in	  a	  clinical	   setting	   could	   thereby	   by	   approximated	   to	   41%,	   as	   48	   of	   117	   eligible	  patients	  would	   have	   started	   treatment	   and	   participated	   in	   the	   post-­‐treatment	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assessment.	  Compared	  to	  the	  other	  studies,	  this	  study	  had	  much	  larger	  rates	  of	  dropout	  after	  inclusion	  and	  randomization.	  Given	  that	  the	  previous	  studies	  had	  samples	  selected	  by	  referral	  or	  self-­‐referral,	  this	  difference	  is	  not	  surprising.	  The	  consecutive	  recruitment	  probably	  resulted	  in	  a	  sample	  that	  was	  less	  motivated	  to	  engage	   in	  treatment	  within	  a	  clinical	   trial.	   In	   light	  of	   this,	  a	  41%	  completion	  rate	   could	   be	   viewed	   as	   the	   minimum	   acceptance	   rate	   of	   ICBT	   in	   a	   clinical	  setting.	   If	   all	   study-­‐related	   activities,	   such	   as	   extensive	   assessments	   and	  randomization,	   were	   removed	   the	   acceptance	   rate	   would	   probably	   have	   been	  higher.	   Also,	   because	   of	   the	   study	   design,	   patients	   who	   were	   prescribed	  antidepressants	  were	   excluded.	   In	   a	   clinical	   setting	   they	  would	   probably	   have	  been	   offered	   ICBT	   if	   symptoms	   still	   remained	   after	   the	   pharmacological	  treatment.	   Based	   on	   this,	   it	   is	   reasonable	   to	   believe	   that	   at	   least	   50%	   of	  outpatients	  at	  a	  gastroenterological	  clinic	  would	  complete	  exposure-­‐based	  ICBT	  with	  effects	  similar	  to	  the	  self-­‐selected	  samples.	  Study	   V	   evaluated	   the	   specificity	   of	   the	   exposure-­‐based	   protocol	   by	   pitting	   it	  against	  a	  stress	  management	  protocol.	  In	  light	  of	  the	  previous	  studies	  (125,	  129,	  131)	  that	  had	  failed	  to	  show	  superiority	  of	  CBT	  compared	  to	  a	  credible	  control,	  we	  judged	  it	  necessary	  to	  put	  our	  treatment	  to	  the	  same	  test.	  We	  made	  sure	  to	  power	   the	   study	  so	   that	  meaningful	  between-­‐groups	  effects	   could	  be	  detected.	  Although	   the	   between-­‐groups	   effects	   on	   IBS-­‐specific	   measures	   were	   rather	  small,	   between	  0.33	   and	  0.52	   at	   post-­‐treatment,	   these	   results	   are	   still	   of	   great	  importance.	  They	  clearly	  show	  that	   the	  effects	  of	  exposure-­‐based	   ICBT	  are	  not	  due	   to	   attention	   from	   a	   caregiver,	   credibility	   of	   a	   treatment,	   or	   expectancy	   of	  improvement.	  The	  differences	  in	  outcome	  between	  the	  treatments	  are	  the	  result	  of	  the	  specific	   ingredients	   in	  the	  ICBT	  condition	  and	  not	  non-­‐specific	   factors.	   It	  could	  be	  argued	  that	  the	  study	  also	  shows	  that	  it	  is	  better	  to	  engage	  in	  exposure	  exercises	   than	   in	   the	   symptom	   control	   strategies	   that	  were	   used	   in	   the	   stress	  management	   condition.	   From	   a	   theoretical	   point	   of	   view	   this	   is	   a	   reasonable	  assumption	  as	  fear	  of	  symptoms	  and	  related	  avoidance	  behaviors	  seem	  to	  be	  key	  maintaining	   factors	   in	   IBS,	  and	  these	   factors	  were	  not	   the	  explicit	   target	   in	   the	  stress	  management	  treatment.	  However,	  study	  V	  was	  not	  primarily	  designed	  to	  compare	   two	   distinct	   treatment	   strategies.	   The	   stress	   management	   treatment	  was	   not	   written	   by	   experts	   in	   that	   line	   of	   IBS	   treatment	   while	   the	   exposure-­‐based	  treatment	  is	  based	  on	  clinical	  experience	  in	  CBT	  for	  IBS	  with	  emphasis	  on	  acceptance	  and	  behavioral	  flexibility.	  It	  should	  also	  be	  noted	  that	  we	  have	  a	  bias	  towards	  favoring	  ICBT	  over	  the	  stress	  management	  treatment.	  Notwithstanding	  these	   limitations,	   study	   V	   indicates	   that	   exposure-­‐based	   CBT	   is	   superior	   to	  symptom	  control	  strategies.	  
4.2 CONTEXTUALIZING	  How	  does	  the	  treatment	  work?	  Although	  we	  observed	  improvements	  in	  the	  “GI	  symptom-­‐specific	   anxiety”-­‐construct,	   using	   the	   visceral	   sensitivity	   index,	   we	  have	   not	   performed	   any	   meditational	   analyses.	   Simple	   correlational	   analyses	  showing	   no	   associations	   between	   changes	   in	   symptoms	   and	   changes	   in	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symptom-­‐related	  fear	  would	  be	  an	  indication	  that	  the	  proposed	  mechanisms	  are	  not	   correct.	   However,	   the	   visceral	   sensitivity	   index	   might	   not	   be	   sensitive	  enough	  to	  capture	  change	  in	  symptom-­‐related	  fear	  and	  avoidance	  behaviors	  and	  a	   low	   correlation	   may	   therefore	   be	   uninformative.	   Similarly,	   significant	  correlations	  would	  not	  be	  very	  informative.	  Using	  two	  assessment	  points,	  before	  and	   after	   treatment,	   is	   not	   sufficient	   to	   establish	   a	   mechanism	   of	   action.	   As	  proper	   meditational	   analysis	   requires	   more	   sophisticated	   methods,	   we	   have	  focused	   on	   presenting	   relevant	   outcome	   data	   together	   with	   the	   theory	  underlying	  the	  treatments.	  We	  have,	  however,	  collected	  weekly	  measures	  of	  the	  VSI	   and	   GSRS-­‐IBS	   in	   study	   V	   and	   plan	   to	   analyze	   these	   data	   to	   investigate	  putative	  mechanisms	  of	  action.	  In	  these	  studies,	  we	  deliberately	  used	  a	  minimal	  set	  of	  interventions.	  We	  did	  not	  include	   cognitive	   restructuring	   or	   specifically	   target	   other	   likely	   sources	   of	  stress	   in	   IBS,	   such	   as	   anxiety,	   depression,	   interpersonal	   relationships,	  perfectionistic	   behavior,	   or	   daily	   stressors	   at	   home	   or	   at	  work.	  We	  wanted	   to	  contrast	   our	   treatment	   with	   multicomponent	   treatments	   and	   target	   only	   one	  hypothesized	  mechanism.	  Many	  other	  psychological	  treatments,	  maybe	  with	  the	  exception	  of	  hypnotherapy,	  have	  targeted	  so	  many	  putative	  mechanisms	  that	  it	  is	   difficult	   to	   determine	   what	   mechanisms	   are	   at	   play	   and	   which	   are	   most	  important.	   By	   targeting	   one	   mechanism	   in	   a	   manualized	   minimal	   contact	  treatment,	  we	  have	  obtained	  a	  50%	  treatment	  response.	  In	  light	  of	  this,	  I	  believe	  that	  our	  studies	  make	  an	   important	   theoretical	  and	  conceptual	   contribution	   to	  the	   IBS	   research.	   IBS	   can	   be	   conceptualized	   in	   several	   different	  ways.	   From	   a	  diagnostic	   perspective,	   IBS	   is	   the	   presence	   of	   altered	   bowel	   habits	   and	  abdominal	  pain	  or	  discomfort	  in	  the	  absence	  of	  structural	  lesions	  (1,	  2).	  From	  a	  pathophysiological	   perspective,	   IBS	   is	   a	   disorder	   characterized	   by	   motor	  abnormalities,	   sensory	   dysfunction,	   and	   nervous	   system	   dysregulation	   (207).	  From	   a	   biopsychosocial	   perspective,	   IBS	   is	   an	   organic	   disorder	   modulated	   by	  psychosocial	   factors,	   which	   can	   predispose,	   precipitate,	   and	   perpetuate	   the	  disorder	   and	   affect	   its	   clinical	   manifestation	   and	   outcome	   (208).	   From	   a	  cognitive	  perspective,	  IBS	  is	  a	  dysfunctional	  cognitive	  style	  that	  leads	  to	  negative	  interpretations	  of	  bodily	   symptoms,	  oneself,	   and	   the	  world,	   causing	   stress	  and	  IBS	   symptoms	   (122,	   126,	   130).	   I	  would	   like	   to	   add	  a	   functional	  perspective	   to	  these	   conceptualizations.	   From	   this	   perspective,	   IBS	   can	   be	   understood	   as	   a	  disorder	  characterized	  by	  GI	  symptoms	  and	  learned	  behavioral1,	  cognitive,	  and	  emotional	   responses	   to	   these	   symptoms	   and	   related	   stimuli.	   These	   learned	  responses,	   e.g.	   fear	   of	   symptoms,	   avoidance	   and	   control	   behaviors,	   and	   help-­‐seeking	   behaviors,	   are	   self-­‐perpetuating.	   In	   other	   words,	   IBS	   is	   a	   process	   of	  experiential	   avoidance	  where	   the	   avoided	   stimuli	   are	   related	   to	   GI	   symptoms.	  Whether	  this	  conceptualization	  of	  IBS	  is	  better	  than	  any	  other	  conceptualization	  is	   an	   empirical	   question.	   According	   to	   the	   “pragmatic	   truth	   criterion”	   (209),	   a	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Strictly	  speaking	  the	  overt	  behavioral	  part	  of	  the	  response	  should	  be	  denoted	  “motor”,	  since	  the	  cognitive	  and	  emotional	  responses	  are	  also	  learned	  behaviors.	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conceptualization	  that	  leads	  to	  a	  desired	  outcome	  is	  a	  correct	  conceptualization.	  Following	  this	  criterion,	  there	  may	  be	  some	  truth	  to	  our	  conceptualization,	  since	  a	  treatment	  based	  on	  it	  has	  led	  many	  IBS	  patients	  to	  report	  less	  suffering	  (which	  is	  our	  desired	  outcome).	  Still,	  with	  a	  50%	  treatment	  response	  rate	  there	   is	  need	  for	   further	  research	  on	  how	  the	  remaining	  50%	  can	  be	  helped.	  Participants	  in	  study	  I	  (group	  treatment)	  showed	  larger	  improvements	  in	  quality	  of	   life	  and	  GI	  symptom-­‐specific	  anxiety	  than	   participants	   in	   the	   other	   studies	   did.	   Maybe	   some	   patients	   need	  individualized	  treatments	  because	  of	  unusual	  behavioral	  patterns	  or	  inability	  to	  work	   independently	  with	   the	   treatment.	   Continued	   face-­‐to-­‐face	  work	  with	   IBS	  patients	  may	  also	   feed	  clinical	  experience	   into	  the	  ICBT	  manuals,	  making	  them	  applicable	   to	   more	   patients.	   The	   conceptualization	   may	   also	   have	   to	   be	  broadened	   and	   include	   other	   sources	   of	   stress	   than	   experiential	   avoidance.	   In	  the	  Background,	   it	  was	   stated	   that	   there	   is	  mixed	  support	   for	  multicomponent	  CBT.	   However,	   the	   minimal	   contact	   multicomponent	   CBT	   interventions	   that	  were	  published	  between	  2008	  and	  2010	  (145-­‐147,	  176)	  all	  show	  sizeable	  effects	  on	   IBS	   symptoms.	   Both	   Lackner	   et	   al.	   (145)	   and	   Moss-­‐Morris	   et	   al.	   (147)	  emphasized	  that	  the	  CBT	  protocols	  in	  their	  studies	  were	  based	  on	  empirical	  and	  clinical	   observations,	   perhaps	   explaining	   their	   success.	   If	   future	   studies,	  preferably	   using	   credible	   control	   conditions,	   show	   similar	   effects	   it	   should	   be	  investigated	  which	  interventions	  in	  these	  protocols	  are	  effective.	  Perhaps	  adding	  cognitive	  restructuring	  as	  a	  therapeutic	  tool	  would	  enhance	  the	  effectiveness	  of	  our	   treatment.	   Indeed,	   the	   imaging	   study	   by	   Lackner	   et	   al.	   indicated	   that	  cognitive	   restructuring	   decreases	   fear	   of	   and	   vigilance	   towards	   IBS	   symptoms	  (97).	   Targeting	   other	   sources	   of	   stress,	   such	   as	   depression,	   anxiety,	   daily	  stressors,	  or	  interpersonal	  relationships	  could	  also	  be	  a	  valuable	  addition.	  What	   should	   the	   treatment	   be	   called?	   It	   is	   important	   to	   point	   out	   it	   is	   not	  acceptance	  and	  commitment	  therapy	  or	  mindfulness-­‐based	  cognitive	  therapy,	  or	  any	   other	   defined	   treatment	   within	   the	   third	   wave	   of	   CBT.	   Compared	   to	   our	  treatment,	  ACT	  is	  much	  less	  focused	  on	  symptom	  relief	  (209)	  and	  mindfulness-­‐based	   cognitive	   therapy	   and	   the	   mindfulness-­‐based	   stress	   reduction	   program	  contain	  at	  least	  4-­‐5	  times	  more	  training	  in	  mindfulness	  (160).	  In	  the	  papers,	  the	  treatment	   has	   been	   called	   “exposure	   and	   mindfulness-­‐based	   therapy”,	   “CBT	  based	   on	   exposure	   and	   mindfulness”,	   “exposure	   treatment”,	   and	   “exposure-­‐based	   CBT”.	   Clearly,	   we	   have	   found	   it	   difficult	   to	   find	   one	   name	   for	   the	  treatment.	  In	  this	  thesis,	  it	  has	  been	  referred	  to	  as	  “exposure-­‐based	  CBT”.	  I,	  now,	  believe	   that	   this	   is	   the	   best	   title.	   Traditional	   CBT	   includes	   homework,	  discussions	   about	   cognitions,	   treatment	   goals,	   behavior	   change,	   structuring	   of	  the	   treatment,	   focus	  on	   the	   current	   life	   situation,	   explicit	   advice	   and	  guidance,	  and	  a	  treatment	  rationale	  (210).	  All	  these	  elements	  are	  present	  in	  our	  treatment.	  However,	  the	  treatment	  does	  not	  contain	  cognitive	  restructuring	  but	  is	  focused	  on	   exposure	   exercises,	   separating	   it	   from	   many	   other	   CBT	   protocols.	   This	  deserves	   to	  be	  stated	   in	   the	  name.	  But	  having	  “mindfulness”	   in	   the	   title	  placed	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the	  treatment	  under	  the	  “mindfulness	  meditation”	  heading	  in	  a	  recent	  review	  of	  psychological	   treatments	   for	   IBS	   (208).	   In	   the	   end,	   the	   best	   description	   of	   a	  treatment	  is	  not	  given	  by	  its	  name	  but	  by	  explaining	  the	  theoretical	  basis	  for	  it	  and	   the	   actual	   interventions	   that	   are	   used.	   I	   believe	   this	   is	   provided	   in	   this	  thesis.	  
4.3 LIMITATIONS	  Important	  methodological	  limitations	  of	  the	  individual	  studies	  are	  highlighted	  in	  the	   previous	   section.	   However,	   some	   issues	   regarding	   generalizability	   remain.	  First,	  as	  seen	  in	  Table	  1,	  64%-­‐74%	  of	  the	  ICBT	  patients	  had	  studied	  at	  university.	  In	  the	  Swedish	  population,	  32%	  between	  the	  age	  of	  25	  and	  64	  have	  a	  university	  degree	   (211).	   As	   discussed	   in	   the	   background	   of	   the	   thesis,	   ICBT	   requires	   the	  patient	  to	  be	  able	  to	  work	  independently	  and	  apply	  the	  treatment	  model	  to	  his	  or	   her	   behavioral	   pattern.	   Suitability	   for	   ICBT	   and	   level	   of	   education	   may	  therefore	  be	  correlated.	  Second,	  most	  IBS	  patients	  are	  diagnosed	  and	  treated	  in	  primary	  care	  (212).	  As	  we	  have	  not	  had	  primary	  care	  as	  recruitment	  base	  we	  do	  not	  know	  if	  our	  results	  can	  be	  generalized	  to	  the	  larger	  IBS	  population.	  Finally,	  diagnostic	   criteria	   have	   been	   developed	   to	   aid	   in	   positive	   diagnosis	   and	  research,	   but	   do	  not	   define	   IBS.	   IBS	   is	   the	  presence	  of	   symptoms	   in	   the	   lower	  gastrointestinal	   tract,	   primarily	   abdominal	   pain	   or	   discomfort,	   constipation,	  and/or	   diarrhea,	   which	   cannot	   be	   explained	   by	   any	   structural	   lesions	   (1,	   2).	  Many	   patients	   who	   identify	   themselves	   as	   having	   IBS	   do	   not	   fulfill	   diagnostic	  criteria	   (16),	   the	   agreement	   between	   a	   clinical	   diagnosis	   and	   a	   criteria-­‐based	  diagnosis	  of	  IBS	  is	   low	  (213),	  and	  clinical	  guidelines	  have	  stated	  that	  the	  Rome	  criteria	  are	  too	  narrow	  for	  primary	  care	  (214).	  All	  these	  limitations	  point	  in	  one	  direction.	   Exposure-­‐based	   ICBT	   should	   be	   evaluated	   for	   patients	   with	  representative	  educational	  levels	  that	  have	  been	  diagnosed	  in	  primary	  care.	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5. CONCLUSIONS	  An	  aim	  of	  the	  thesis	  was	  to	  investigate	  the	  overall	  effectiveness	  and	  usefulness	  of	  exposure-­‐based	   CBT	   for	   IBS.	   The	   studies	   included	   in	   the	   thesis	   show	   that	   the	  treatment	   is	   effective	   in	   group	   and	   delivered	   via	   the	   internet.	   It	   targets	  symptoms,	   fear	   of	   symptoms,	   and	   related	   avoidance	   behaviors,	   quality	   of	   life,	  and	   also	   comorbid	   psychiatric	   problems.	   It	   has	   specific	   short-­‐	   and	   long-­‐term	  effects	   and	   is	   useful	   for	   referred,	   self-­‐selected,	   and	   tertiary	   care	   IBS	   patients.	  Further	   analyses	   have	   also	   shown	   that	   it	   is	   associated	   with	   societal	   cost	  reductions.	  My	   hope	   is	   that	   this	   thesis	   will	   contribute	   to	   the	   understanding	   and	   future	  treatment	  of	  irritable	  bowel	  syndrome.	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  participating	  in	  the	  psychiatric	  screening	  of	  the	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  cost-­‐effectiveness	  article	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  when	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  Filip	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  you	  for	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  and	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Monica	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  see	  other	  sides	  of	  the	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Peter	  Csatlós.	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